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Bacterial vaginosis (BV) is a common vaginal condition affecting reproductive-age women, 
especially in sub-Saharan Africa. With poor treatment outcomes, BV has been associated with 
pregnancy complications, pelvic inflammatory disease as well as acquisition and transmission of 
sexually transmitted diseases. While the etiology of BV is not well characterized, it is understood 
that Gardnerella vaginalis plays a critical role in BV by initiating the formation of the 
polymicrobial biofilm that characterizes BV and by degrading protective vaginal mucus through 
the release of sialidase. Recent evidence suggests that the G. vaginalis species is more 
heterogeneous that initially thought and that not all G. vaginalis may be involved BV. The aim of 
this study was thus to characterize the genotypic and phenotypic diversity of G. vaginalis 
isolates. This was achieved in vitro, using 109 G. vaginalis isolates that were previously purified 
from vaginal samples of 109 French women who were BV-positive (n = 75), BV-intermediate (n 
= 20) or BV-negative (n = 14), as diagnosed by Nugent scoring. To determine the genotypic 
diversity of G. vaginalis isolates, 90 isolates were successfully genotyped using their 
chaperonin-60 (cpn60) sequences, revealing the presence of four phylogenetic clades 
(subgroups A-D) made up of 13 subgroup A, 17 subgroup B, 58 subgroup C and 2 subgroup D 
isolates. To determine the phenotypic diversity of G. vaginalis isolates, sialidase activity, biofilm 
formation and susceptibility to antibiotics used to treat BV were measured. Sialidase activity was 
not detected in subgroup A and D isolates but was detected, at similar levels, in subgroup B and 
C isolates. Isolates from all subgroups of G. vaginalis could form similar amounts of biofilm. G. 
vaginalis isolates (n = 45) were largely resistant to metronidazole (71%), but sensitive to 
clindamycin (100%), moxifloxacin (91%) and augmentin (100%). The presence of prophages in 
G. vaginalis isolates was also investigated, revealing the presence of bacteriophage (phage)-
like particles that could not be classified into any known phage families, whose phage status 
remains to be confirmed. In conclusion, G. vaginalis subgroup B and C isolates were the only 
ones that formed biofilm as well as had detectable sialidase activity suggesting that G. vaginalis 
subgroups B and C are most likely to be involved in BV. These results contribute to our 
knowledge of BV and could be useful in future studies that aim to design better treatment 
strategies for BV. 
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Chapter 1: Introduction 
 
1.1 Bacterial vaginosis (BV) 
BV is a common vaginal condition affecting reproductive-age women globally, with a 
prevalence ranging from 4.5-24% in Europe and 6-58% in sub-Saharan Africa during 
1984-2011 (1). A recent study in 2015 revealed a 31% prevalence rate of BV in South 
African women (2). However, these statistics underestimate the actual prevalence of BV 
as more than half of BV-positive women are asymptomatic and thus do not get tested or 
are misdiagnosed as BV-negative when they are in fact BV-positive (3). BV is often 
considered a minor condition as the only symptoms are abnormal vaginal discharge 
with foul odor. However, BV is recurrent and can severely diminish women’s self-
esteem, sexual relationships and quality of life (4). Moreover, BV puts women at a high 
risk of experiencing pregnancy complications and acquiring and transmitting human 
immunodeficiency virus (HIV) as well as other sexually transmitted infections (5). This 
stresses the need for effective clinical strategies to manage BV. Unfortunately, this is 
not the case as the current poor treatment outcomes of BV reflect our poor 
understanding of the etiology of BV (6). It is understood that BV is characterized by a 
dysbiosis of the vaginal microbiota, during which a plethora of facultative or strictly 
anaerobic bacteria exist in a polymicrobial biofilm (7). However, a few fundamental 
question are yet to be addressed, including: (i) what causes the shift from normal to 
diseased state; (ii) is there one or a set of bacteria that serve as the etiological agent(s) 
while the rest of the BV-associated bacteria are merely opportunistic and (iii) which 
bacterial targets would lead to the eradication of the polymicrobial biofilm that forms 
during BV? This study is concerned with the latter question. Answering these questions 
will help us better understand BV pathogenesis, providing knowledge that could be 





1.1.1 Microbiological definition of BV 
There is still much debate on how to define BV in the microbiological context. However, 
BV is often defined as characterized by changes in the vaginal microbiota, that is, a 
decrease in commensal lactic acid-producing bacteria (mostly Lactobacillus species), 
coupled with an increase in number and diversity of facultative or strictly anaerobic BV-
associated bacteria existing in a polymicrobial biofilm (Figure 1.1). This polymicrobial 
biofilm is composed primarily of Gardnerella vaginalis and Atopobium vaginae but also 
contains species such as Prevotella species (P. bivia, P. dentalis, P. buccalis, P. 
timonensis and P. amii), Megasphaera species (M. elsdenii and M. micronuciformis), 
Sneathia sanguinegens, Eggerthella hongkongensis, Mobiluncus mulieris, 
Fusobacterium gonidiaformans, Leptotrichia amnionii,  Aerococcus christensenii, 
Parvimonas micra, Peptoniphilus species (P. lacrimalis, P. asaccharolyticus and P. 
methioninivorax), Porphyromonas asaccharolytica, Dialister micraerophilus, as well as 
novel BV-associated bacteria (BVAB) 1-3 belonging to the Clostridiales order (8-11). 
The broad relevance of this definition has been brought into question by studies 
revealing that, while the vaginal tracts of healthy white and Asian women are dominated 
by Lactobacillus species, the vaginal tracts of many healthy black or Hispanic women 
are not, but are in fact dominated by what are described as BV-associated bacteria (10, 
12, 13). In addition to producing hydrogen peroxide and bacteriocins that are toxic to 
BV-associated bacteria, Lactobacillus species maintain acidic vaginal conditions 
through the production of lactic acid, providing a healthy vaginal environment that does 
not support the growth of pathogenic bacteria (14). However, some BV-associated 
bacteria such as Atopobium and Leptotrichia species also produce lactic acid (15, 16), 
suggesting a possible mechanism by which vaginal health can be maintained in a non-
lactobacilli-dominated vaginal tract (13, 17). These findings suggest a need to redefine 
BV in the context of ethnic diversity, as the current definition enables a reality where 
healthy black and Hispanic women are misdiagnosed as BV-positive, contributing to the 




A hypothesis that has been posed to explain the ethnic differences in vaginal microbial 
profiles associated with health is the possibility that some BV-associated bacteria can 
play dual roles as commensal microbes or pathogens (18), depending on other factors 
such as the presence or absence of Lactobacillus species, availability of glucose and/or 
BV status. Another possible hypothesis is that intra-species diversity separates 
commensal from pathogenic BV-associated bacteria, and that healthy black or Hispanic 
women are colonized by commensal subtypes of BV-associated bacteria. It is thus 
important to study in detail, the diversity of each BV-associated species as this could 
shed light on ethnicity-based differences in microbial profiles of healthy women, as well 
as help us better understand the etiology of BV.  
  
1.1.2 BV symptoms and diagnosis 
BV is most commonly diagnosed using Amsel’s criteria (19) or Nugent scoring (20).   
Amsel’s criteria considers BV-positive as presenting with at least three of the following: 
(i) vaginal pH above 4.5, (ii) thin homogeneous vaginal discharge (iii) containing 
epithelial cells coated with bacilli (clue cells) and/or (iv) releasing a fishy odor upon 
treatment with 10% potassium hydroxide (whiff test). A limitation of Amsel’s criteria is 
that it cannot be used to diagnose asymptomatic BV-positive women, with one study 
finding a 63% (34/54) false negative rate (21).  Nugent scoring is thus more commonly 
used to diagnose BV, that is, scoring vaginal Gram-stained smears from 0-10 based on 
the presence of large Gram-positive rods (Lactobacillus morphotype, scored 4-0), small 
Gram-variable rods (G. vaginalis or Bacteroides morphotype, scored 0-4), and curved 
Gram-negative rods (Mobiluncus morphotype, scored 0-2) with scores of 0-3, 4-6 and 7-
10 indicating BV-negative, BV-intermediate and BV-positive, respectively (20). While 
Nugent scoring can diagnose asymptomatic BV-positive women, it also has its 
shortcomings as it can result in false positives in particularly black or Hispanic women, 
whose healthy microbiota is not dominated by Lactobacillus species (10, 12, 13). 
Another tested strategy to diagnose BV is using polymerase chain reaction (PCR) 
primers specific for BV-associated bacteria (22-25); although, these sensitive nucleic 
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acid amplification tests have the same limitation as Nugent scoring (high rates of false 
positives) as this strategy is based on the false assumption that there exists a core 
microbial signature, differentiating healthy from BV-positive microbiota (10). Another 
method used to diagnose BV is using the Osem BVBlue® test, a rapid BV diagnostic 
test that detects levels of sialidase activity in vaginal secretions (26). Sialidase, a 
mucolytic enzyme secreted by G. vaginalis and Prevotella species, is elevated in 69-
84% of vaginal secretions from BV-positive women (27-29). However, the detection of 
sialidase activity alone is not adequate enough to diagnose BV as sialidase activity is 
also detected in 3.2-6% of BV-negative women (29, 30). A combination of these tests 
have been used in effort to increase the sensitivity and specificity of BV diagnosis (31); 
although, there is still an urgent need to develop a more accurate test that can diagnose 





Figure 1.1: Vaginal bacterial composition in BV-positive and BV-negative women. BV 
status according to (A) Amsel’s criteria and (B) Nugent score is shown in the two vertical bars 
upon which (C) bacterial taxa (according to 16S rRNA genes) are stratified. Figure adapted from 
Srinivasan et al. (9). 
 
1.1.3 Risk factors for BV 
In addition to ethnic differences (10, 13), there are several other risk factors that have 
been suggested for BV. A meta-analysis of 43 studies conducted between 1992-2007 
suggested that risky sexual behaviors such as having a new or multiple sexual partners 
and a lack of condom use were associated with a modest increased risk of BV 
acquisition, suggesting that BV is sexually associated (32). Considering the lack of 
empirical evidence suggesting BV to be a sexually transmitted condition, while also not 
ignoring the association of BV with risky sexual behavior, BV was termed to be a 
A 
B 




sexually-enhanced condition (33). Menstruation has been described as a risk factor for 
BV as an increase in G. vaginalis and decrease in L. crispatus during menses has been 
observed (11, 34, 35). However, these were transient changes, which lasted as long as 
the duration of menstruation; thus, this claim remains to be confirmed. Douching has 
also been associated with BV, presumably due to the bacterial disequilibrium and/or 
inflammation (chemical or physical) brought about by douching  (36). Interestingly, 
smoking has also been associated with increased risk of BV. This is thought to be due 
to the action of benzo[a]pyrene diol epoxide (BPDE) from cigarette smoke in the female 
genital tract, which may promote induction of prophages of Lactobacillus species in 
vitro, leading to their decline (37). It is difficult to determine the direct mechanisms by 
which these events contribute to BV as the etiology of BV is poorly understood; thus, 
most of these risk factors are still being debated. 
 
1.1.4 Treatment of BV 
The recommended first-line regimens for BV antibiotic treatment are: (i) 500mg oral 
metronidazole twice a day for 7 days; (ii) 5g of 0.75% metronidazole intra-vaginal gel 
once a day for 5 days or (iii) 5g of 2% clindamycin intra-vaginal cream at bedtime for 7 
days (38). However, BV treatment failure rates are substantial, with one study finding 
that, of 104 women treated with either metronidazole or clindamycin antibiotics, 49% 
experienced treatment failure within one month (6). In addition, BV recurrence occurs at 
an alarming rate  with  another study showing that more than 50% of 130 women had at 
least one recurrent BV episode within a year (39). One reason for this treatment failure 
could be antibiotic resistance. Indeed, it is becoming increasingly clear that some BV-
associated bacteria have acquired resistance to metronidazole and/or clindamycin (40-
43). In addition to antibiotic resistance, the biofilm forming ability of BV-associated 
bacteria could also be contributing to the high BV recurrence rate as antibiotic-sensitive 
bacteria may be protected inside an antibiotic-impenetrable biofilm, rendering antibiotic 
treatment ineffective (44). There is thus a great need to explore alternative BV 
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treatments, which is particularly difficult in the case of BV as its etiology is poorly 
understood. 
 
1.1.5 Complications of BV 
BV has been associated with poor reproductive health outcomes (45). BV may increase 
risk of developing pelvic inflammatory disease, possibly due to BV-associated bacteria 
from the lower female genital tract ascending to the upper genital tract causing 
inflammation of the uterine lining and/or fallopian tubes, thus possibly linking BV to 
infertility (46). This ascension is particularly problematic in pregnant women as BV has 
been linked to adverse pregnancy outcomes including preterm delivery, premature 
rupture of membranes (PROM) and postpartum endometritis (45, 47). BV has also been 
associated with the acquisition and/or transmission of several sexually transmitted viral 
infections, including HIV, cervical human papillomavirus (HPV) and herpes simplex 
virus-2 (HSV-2), as well as bacterial infections caused by Neisseria gonorrhoeae and 
Chlamydia trachomatis (48-52). Several hypotheses have been proposed to explain the 
increased susceptibility of BV-positive women to sexually transmitted infections, 
including: (i) higher genital inflammation during BV resulting in infiltration of HIV target 
cells (53, 54); (ii) mucolytic sialidase activity is higher in BV-positive women, thus, the 
protective mucus lining that coats the epithelial cell layer would be diminished during 
BV, enhancing access of HPV and HSV-2 to their epithelial cell targets (50, 51) and (iii) 
lack of lactobacilli-produced hydrogen peroxide during BV, which would otherwise be 
toxic to pathogens such as N. gonorrhoeae and C. trachomatis (52). With such grave 
potential consequences, it is necessary to design effective prophylaxis and treatment 
strategies for BV.  
 
1.2 Gardnerella vaginalis  
G. vaginalis is well accepted to be BV-associated, being present in the vaginal tracts of 
97-100% of BV-positive women (8, 9). They are Gram-positive, facultative anaerobic, 
0.3-0.5 μm wide, 1-3 μm long bacilli that form 0.05-0.2mm diameter colonies on blood-
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supplemented agar after 48 h at 37°C (55, 56). Initially classified as Haemophilus 
vaginalis by Gardner and Dukes in 1955, they were thought to be the cause of 
nonspecific bacterial vaginitis (55), the condition now referred to as BV. After DNA-DNA 
hybridization assays in the 1980’s revealed no genetic relationship between 
Haemophilus vaginalis and other members of this genera, Haemophilus vaginalis was 
reclassified as G. vaginalis (56). In addition to being present in the vaginal tract, G. 
vaginalis has been isolated from various female mucosal surfaces, including the 
endometrium (57), anus (58), urinary tract (59) and oral cavity (60). Notably, G. 
vaginalis has also been isolated from male urethra and penile skin; moreover, 
monogamous heterosexual couples were shown to share the same strains of G. 
vaginalis, genotyped using unique sequence variants of the G. vaginalis 16S rRNA 
gene (61). This led to the speculation that G. vaginalis is sexually transmitted; however, 
this remains to be confirmed. 
 
1.2.1 Association of G. vaginalis with BV 
G. vaginalis is thought to play a central role in BV pathogenesis (7, 44). While there is 
no core set of microbes that define all cases of BV (10), G. vaginalis is found in virtually 
all (97-100%) BV-positive women (8, 9). While G. vaginalis comprises only up to 5% of 
16S rRNA genes (represented in the peach colour, Figure 1.1), G. vaginalis comprises 
on average 47% of all transcripts in BV, making G. vaginalis the most transcriptionally 
active BV-associated bacteria (62). One study revealed the presence of G. vaginalis to 
be absolutely necessary for BV pathogenesis (63). This is probably because G. 
vaginalis plays a critical role in sialidase production and biofilm formation, two hallmark 
traits of BV (reviewed later in detail in sections 1.2.4 and 1.2.5, respectively). During BV, 
G. vaginalis can act in synergy with other BV-associated bacteria. For example, synergy 
between G. vaginalis and P. bivia was described with regards to energy source cycling, 
where it was postulated that P. bivia produces ammonia, which is utilized by G. 
vaginalis, which subsequently produces amino acids, which are utilized by P. bivia in 
order to produce ammonia (64). In a dual-species biofilm assay, growth of G. vaginalis 
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was increased by the presence of A. vaginae, F. nucleatum, M. mulieris and P. bivia, 
while in turn, growth of P. bivia was increased by the presence G. vaginalis (65). In a 
subsequent dual-species biofilm assay, performed by the same researchers, G. 
vaginalis strains isolated from BV-negative women showed synergy with M. mulieris (a 
BV-associated pathogen), while those from BV-positive women antagonized M. 
mulieris, a curious observation that was contrary to what was expected, which warrants 
further research (66).   
 
Although well-described in BV pathogenesis, G. vaginalis can also be found in genital 
tracts of BV-negative women (10). To quantify G. vaginalis bacterial loads in BV-
negative and BV-positive women, Balashov et al. (67) used the tuf gene, which encodes 
the translation elongation factor, Tu, as it was shown to be more reliable than 16S rRNA 
in quantifying G. vaginalis bacterial load because G. vaginalis harbors only one copy of 
the tuf gene as opposed to multiple copies of the 16S rRNA gene. This study revealed 
an important observation that, while BV-positive women harbor high G. vaginalis 
bacterial loads, BV-negative women can harbor either high or low G. vaginalis bacterial 
loads, suggesting that there is subset of G. vaginalis that are not involved in BV, even if 
present at high concentrations (Figure 1.2). However, phenotypic traits differentiating 







Figure 1.2: High G. vaginalis load is associated with BV. DNA concentration of 60 G. 
vaginalis isolates as characterized according to (A) Amsel criteria and (B) Nugent scores. 
Figure adapted from Balashov et al. (67). 
 
1.2.2 Phenotypic heterogeneity of G. vaginalis 
The heterogeneity of G. vaginalis was initially elucidated through the use of a biotyping 
scheme designed by Piot et al. (68) that was based on biochemically testing G. 
vaginalis isolates for hippurate hydrolysis, β-galactosidase and lipase activity. Using this 
biotyping scheme, 8 biotypes were identified with more than 80% of the screened 359 
G. vaginalis isolates belonging to three biotypes. However, since the chosen 
biochemical markers were not related to BV virulence, no biotypes were found to be 
predictive of BV. Nonetheless, this biotyping scheme has been used multiple times 
since, with opposing conclusions with regards to associations of some biotypes with BV 
(67, 69-72). Furthermore, differences in methodology used to test activities of the three 
biochemical markers, particularly lipase activity, were shown to greatly influence results, 
leading to erroneous biotyping (73). Recently, this biotyping scheme has been 
abandoned for tests based on relevant BV phenotypes, such as sialidase and biofilm 





1.2.3 Genotypic heterogeneity of G. vaginalis 
In an effort to genotype G. vaginalis, traditional assays such as amplified ribosomal 
DNA restriction analysis (ARDRA) and random amplified polymorphic DNA (RAPD) 
analysis revealed the presence of up to three genotypes of G. vaginalis (67, 71, 72, 74, 
75). While none of these studies revealed any genotype-specific associations with BV, 
only two out of the three genotypes of G. vaginalis demonstrated sialidase activity, 
implicating the two genotypes in BV pathogenesis (75). These DNA fingerprinting 
methods have recently been replaced with modern sequence-based methods of 
genotyping.  
 
It has been well accepted that there is only one species of Gardnerella, that is G. 
vaginalis; however, whole genome sequencing of 17 G. vaginalis isolates revealed the 
presence of four clades of G. vaginalis, with sufficient divergence from each other to be 
considered four distinct species (57). Although, phenotypic traits differentiating the 
clades would need to be established before reclassifying G. vaginalis as having four 
species (76). The same four clades of G. vaginalis could be discriminated by 
phylogenetic analysis of a 552 base-pair (bp) region of the chaparonin-60 (cpn60) 
housekeeping gene, into subgroups A, B, C and D by Jayapraesh et al. (72) 
corresponding to whole genome sequence clades 4, 2, 1 and 3 in Ahmed et al. (57), 
respectively. Multiple studies have since genotyped G. vaginalis into two to four 
subgroups using cpn60 sequence analysis (27, 67, 77). Generally, studies have shown 
that most women harbor multiple subgroups of G. vaginalis, with subgroup diversity 
being predictive of BV; although, there is still debate over which subgroups of G. 
vaginalis are associated with BV (67, 72, 78, 79). Jayaprakesh et al. (72) conducted a 
study using 44 vaginal samples, 20 (45%) of which were from BV-positive women and 
found subgroup B to be the only BV-associated subgroup. However, Balashov et al. 
(67) used 59 vaginal samples, 22 (37%) from BV-positive women, and found subgroups 
C and D to be BV-associated. Using a larger sample size of 75 vaginal samples, 29 
(27%) of which were from BV-positive women, Janulaitiene et al. (78) found subgroup B 
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and C to be BV-associated. One reason for the discrepancies between the studies 
could be the differences in sample size and prevalence of each subgroup, that is, low 
prevalence of some G. vaginalis subgroups may limit the statistical power to test the 
association between these G. vaginalis subgroups and BV. For example, Jayaprakesh 
et al. and Janulaitiene et al., who both found subgroup B to be BV-associated, detected 
this subgroup in 97.7% (43/44) and 42.7% (32/75) of their samples, respectively. In 
contrast, Balashov et al, who did not find subgroup B to be BV-associated, detected 
subgroup B in only 25.4% (15/59) of their samples, a figure that was reduced even 
further after separating the subgroup B samples according to their BV-negative, BV-
intermediate and BV-positive status, thus further limiting this subgroup’s statistical 
power. Further studies using larger cohorts are required to test these associations as 
they are imperative in identifying which G. vaginalis subgroups to target in BV therapy. 
 
1.2.4 Role of G. vaginalis sialidase activity in BV pathogenesis 
G. vaginalis contributes to the elevated sialidase activity levels seen in BV-positive 
versus BV-negative women (27-29). G. vaginalis is thought to secrete sialidase to 
cleave immunoglobulin A (IgA) sialic acids residues as well as the sialic acids that make 
up the protective mucus layer that lines vaginal epithelium (80). Additionally, sialidase-
activity-positive G. vaginalis isolates internalize, catabolize and deplete vaginal sialic 
acids (80). It is important to note that not all G. vaginalis harbor the sialidase gene as it 
was detected only 49-75% of G. vaginalis isolates screened across different studies (27, 
75, 81). Moreover, not all G. vaginalis isolates with the sialidase gene demonstrate 
sialidase activity (72, 75, 80). Jayaprakesh et al. (27) showed that, while the sialidase 
gene was detected in all 33 subgroup B, 35 subgroup C and 8 subgroup D isolates, the 
sialidase gene was detected in only 1/36 subgroup A isolates. Additionally, while all 33 
subgroup B isolates had detectable sialidase activity, only a minority of subgroup C 
isolates (3/35) and none of the subgroup A and D isolates had detectable sialidase 
activity. Notably, as subgroup B was previously associated with BV (72), the finding that 
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all isolates from this subgroup had detectable sialidase activity strongly implicates 
subgroup B as actively involved in BV (27). 
 
A recent study by Hardy et al. (81) found an association between BV and high 
quantitative-PCR (qPCR) loads of the G. vaginalis sialidase gene in vaginal specimens. 
Moreover, Hardy et al. are the first to show an association between G. vaginalis 
sialidase gene loads and biofilm formation. They postulated that G. vaginalis uses 
sialidase to break down protective vaginal mucus, allowing it easier access to vaginal 
epithelium to form adherent biofilms, a phenomenon that has been described for other 
organisms such as Pseudomonas aeruginosa and Streptococcus pneumoniae (82, 83). 
It is thus necessary to test sialidase activity and biofilm formation in the same isolates 
that are genotyped into the four subgroups of G. vaginalis as this will provide novel 
information that could identify G. vaginalis subgroups involved in BV.  
   
1.2.5 Role of G. vaginalis biofilm formation in BV pathogenesis  
An adherent polymicrobial biofilm is a hallmark trait of BV, being present on vaginal 
epithelial cells of 90-97% of biopsy specimens from BV-positive women but only 4-10% 
from BV-negative women (63, 84). It is estimated that G. vaginalis contributes 60-95% 
of the biofilm’s biomass. In an assay measuring epithelial cell adherence of BV-
associated bacteria co-cultured with L. crispatus, G. vaginalis was found to be more 
effective at displacing L. crispatus than the other BV-associated bacteria, including A. 
vaginae, P. bivia and M. mulieris (85). Similarly, another study showed that G. vaginalis 
displayed the highest initial adhesion to epithelial cells and the highest biofilm forming 
ability compared to 29 other BV-associated bacteria (86). These data suggest that G. 
vaginalis may be an early colonizer, initiating the formation of the biofilm, which 
subsequently allows other BV-associated bacteria to colonize the female genital tract, 




G. vaginalis biofilms are thought to play a number of distinct roles in the context of BV. 
G. vaginalis biofilms are strongly associated with BV recurrence (87), discussed later in 
detail (section 1.2.6). Compared to in planktonic form, G. vaginalis in biofilm form 
survived up to five times better in the presence of toxic lactobacilli-produced lactic acid 
and hydrogen peroxide (88), which is possibly the mechanism that G. vaginalis uses to 
survive in healthy lactobacilli-dominated vaginal tracts (10, 84). In addition to the vaginal 
tract, G. vaginalis has also been shown to form biofilm in the endometrium of BV-
positive women, possibly linking G. vaginalis to the adverse pregnancy outcomes 
associated with BV (7). 
 
With regards to the differences in biofilm forming ability amongst the four subgroups of 
G. vaginalis, there has only been one report, which revealed that all four subgroups are 
capable of forming biofilm (72). This was a report of a qualitative assay that detected 
the absence or presence of biofilm thus, it remains to be seen if some subgroups 
produce more biofilm than others. This information could be useful in determining which 
subgroups play an important role in the formation of biofilm and thus, which subgroups 
to target when aiming to eliminate the polymicrobial biofilm that forms during BV. 
 
1.2.6 Role of G. vaginalis in poor BV treatment outcomes  
As discussed earlier (section 1.1.4), the current standard of care for BV is antibiotic 
treatment with  metronidazole or clindamycin (38), but this treatment fails up to 50% of 
the time (6) and recurrence is common (39). Recurrence could be due to the antibiotic-
impenetrable biofilm that forms during BV (87), that is, antibiotics are not always able to 
reach the center of biofilms as they can get used up by bacteria in the exterior layers of 
biofilms (89). BV biofilms are thought to be initiated by G. vaginalis (44); moreover, G. 
vaginalis biofilms have been shown to persist in women after they were treated for BV 
with metronidazole (87). Therefore, strategies targeting G. vaginalis biofilms may 




As BV is a recurrent condition, women often have to get retreated multiple times (6). It is 
thus not surprising that BV-associated bacteria such as G. vaginalis have acquired 
resistance to antibiotics used in the treatment of BV. This is particularly true for 
metronidazole, with reported resistance rates ranging from 61-68% amongst G. 
vaginalis isolates (41-43). Moreover, the majority of metronidazole-resistant G. vaginalis 
isolates are highly resistant, that is, require more than 256 μg/ml metronidazole to inhibit 
growth (41, 42). A study that compared metronidazole susceptibility amongst G. 
vaginalis subgroups, using 87 isolates, showed that all subgroup A and D isolates were 
metronidazole-resistant (22/22 and 14/14 isolates, respectively) compared to only 35% 
(16/37) subgroup C and 7% (1/14) subgroup B isolates (41). Compared to 
metronidazole, clindamycin resistance among G. vaginalis isolates is lower, ranging 
from 1.5-6% (42, 43) and is thus considered a good alternative in the event of 
metronidazole treatment failure. In addition to clindamycin, moxifloxacin and augmentin 
could be considered good alternatives in the event of metronidazole treatment failure as 
they have demonstrated good BV treatment outcomes (90, 91); although, G. vaginalis 
susceptibility to these antibiotics is not well studied. It could be useful to study 
clindamycin, moxifloxacin and augmentin susceptibility of G. vaginalis and to compare it 
to metronidazole susceptibility, using the same set of isolates, as this could yield 
information on which antibiotics could serve as the best alternative to metronidazole in 
the management of G. vaginalis biofilms present during BV. 
 
1.2.7 Bacteriophages of G. vaginalis 
Genomes of G. vaginalis are known to harbor clustered regularly interspaced short 
palindromic repeats (CRISPR) loci and their associated cas genes (59, 62, 92). Bacteria 
use their CRISPR-cas systems to mount an immune response against foreign DNA, 
especially against DNA of bacteriophage (phages), which are viruses that infect bacteria 
(93). CRISPR loci contain spacer sequences, sequences that are homologous to 
foreign DNA, which are acquired and accumulate with every phage infection (93). 
CRISPR loci can thus be used as evidence for the existence of phages that have 
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previously targeted particular bacteria. Up to 70% of G. vaginalis spacer sequences 
could not be matched to any known bacterial or viral sequences on the GenBank 
database, suggesting that the majority of G. vaginalis phages have yet to be isolated 
and characterized (92).  
 
Phages are most commonly classified as either virulent or temperate, based on the 
types of lifecycles the can undergo after gaining entry into a host cell (94). Virulent 
phages exclusively undergo the lytic lifecycle: a short cycle of replication, assembly of 
phage proteins and host cell lysis upon exit. Temperate phages can undergo the 
lysogenic lifecycle, a state whereby they integrate their phage DNA (prophage) into their 
host’s genome, latently multiplying with the host until environmental stress induces them 
into the lytic lifecycle (94). While virulent phages against G. vaginalis have yet to be 
reported, there have been several reports of the presence of prophage sequences 
within G. vaginalis genomes (59, 95, 96). One of the earliest references of G. vaginalis 
phages was made in 2010, where 10 phage-associated genes (including integrase and 
assembly genes) were found in three G. vaginalis strains (95). Later, another study by 
Malki et al. (59) did a comprehensive analysis of G. vaginalis sequences from the 
National Center for Biotechnology (NCBI) database, which revealed the presence of 
442 prophage sequences, with a median length 939bp, from 39 genomes of G. 
vaginalis from the bladder, vagina and endometrium. The number of phage sequences 
per G. vaginalis genome ranged from 0-33. A total of 104 clusters of orthologous 
prophage genes were identified based on sequence similarity. Half of the 104 prophage 
clusters showed little to no matches to any phage sequences in the GenBank database. 
Of the prophage clusters that could be matched, most resembled an array of different 
bacterial taxa while a few clusters resembled a single bacterial taxon including Bacillus, 
Mycobacterium and Staphylococcus species. All the phages belonged to the 
Siphoviridae family. While prophage homologue sequences in large clusters were highly 
conserved, 49 clusters were made up of a single prophage gene sequence, suggesting 
that G. vaginalis frequently acquires phage sequences independently. Based on their 
estimates of rate of phage acquisition, Malki et al. hypothesized that G. vaginalis 
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prophages can be acquired both through vertical inheritance (from parent to offspring) 
and horizontal gene transfer (from donor to recipient). Their analysis also showed that 
G. vaginalis isolated from the same host can differ in prophage gene content suggesting 
intra-host prophage gene acquisition/loss.  
 
Recently, prophages of G. vaginalis were identified by whole genome sequencing in 
another study by Miller-Ensminger et al. (96), where they were able to identify 
prophages and nonintegrated phages, that is, possible virulent phages and prophages 
existing as extra-chromosomal plasmids. The number of phage sequences per G. 
vaginalis genome ranged from zero to two while for other bacterial taxa, the highest 
number of phage per genome was 10. Of the 21 isolates of G. vaginalis that were 
sequenced, almost half (10/21) had low quality or no prophage detection; while the 
remainder had one integrated phage (9/21), one nonintegrated phage (1/21) or both an 
integrated and a nonintegrated phage detected. It is worth noting that far fewer G. 
vaginalis phages were identified in the study by Miller-Ensminger et al. (average one 
phage per genome; range 0-2; 21 genomes) compared to the study by Malki et al. 
(average 11 phages per genome; range 0-33; 39 genomes). This is most likely due to 
different methods used to identify prophages in the two studies, serving as caution to 
future studies to consider using various phage annotation tools in order to avoid 
underestimating phage populations. Nevertheless, these studies provide strong 
bioinformatic evidence for the presence of G. vaginalis phages, despite the current lack 
of empirical laboratory evidence.  
 
Since there is evidence that prophages of G. vaginalis exist, it is possible that 
Lactobacillus species suppress the growth of G. vaginalis by releasing substances that 
induce prophages of G. vaginalis. This hypothesis follows an observation made in a 
previous study where Streptococcus pneumonia supernatant contained hydrogen 
peroxide, which caused the induction of prophages of Staphylococcus aureus (97). As 
Lactobacillus species such as L. gasseri are known hydrogen peroxide-producers (98), 
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the supernatant of L. gasseri could be tested for its ability to induce prophages of G. 
vaginalis. Mitomycin C, ciprofloxacin and ultraviolet (UV) radiation are commonly used 
to induce prophages of other bacteria as they are DNA-damaging agents that lead to 
the activation of the SOS response, which can trigger the inactivation phage repressor 
genes, resulting in prophage induction (99). As in other studies, these prophage-
inducing agents can be tested for their use as positive controls in the induction of G. 






To characterize the genotypic and phenotypic diversity of vaginal G. vaginalis isolates. 
 
1.3.2 Objectives 
1. To genotype G. vaginalis isolates using cpn60 sequence analysis.  
2. To phenotype G. vaginalis isolates with regards to sialidase activity, biofilm 
formation and susceptibility to antibiotics used to treat BV.  
3. To screen a panel of G. vaginalis isolates for the presence of prophages. 
 
1.3.3 Rationale 
G. vaginalis is thought to contribute to BV pathogenesis by: (i) secreting sialidase, which 
degrades protective vaginal mucus; (ii) forming biofilms that support the growth of other 
BV-associated bacteria and (iii) resisting the antibiotic effects of metronidazole. While 
G. vaginalis is present in virtually all BV-positive women, many BV-negative women can 
harbor high G. vaginalis bacterial loads suggesting that not all G. vaginalis are involved 
in BV. Four phylogenetically distinct subgroups of G. vaginalis have recently been 
identified and it is thought that not all subgroups are involved in BV. This study thus 
aims to investigate the diversity of G. vaginalis isolates with regards to sialidase activity, 
biofilm formation and susceptibility to antibiotics used to treat BV. It is possible that 
Lactobacillus species may suppress the growth of G. vaginalis through releasing 
hydrogen peroxide, which induces prophages of G. vaginalis. Therefore, this study 
further aims to screen a panel of G. vaginalis isolates for the presence of prophages. 
This is the first study to use the same collection of G. vaginalis isolates to quantify 
sialidase activity, biofilm formation and antibiotic susceptibility of G. vaginalis 
subgroups. These results will elucidate the roles the different subgroups of G. vaginalis 
play in the context of BV and could thus identify which subgroups of G. vaginalis to 
target in BV treatment studies.  
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Chapter 2: Materials and Methods 
 
2.1 Samples 
One hundred and nine isolates of G. vaginalis, purified from vaginal samples of women 
routinely visiting Hôpital Arnaud-De-Villeneuve (CHU de Montpellier, France), were 
kindly provided by Dr. Rémy Froissart from the Institut de recherche pour le 
développement (IRD), France (Collaboration Agreement UCT-MIVEGEC, Reference: 
CNRS 174773). The L. gasseri isolate used in this study was kindly provided by Mrs. 
Hoyam Gamieldien (Division of Medical Virology, University of Cape Town), purified 
from a vaginal sample of a woman in Cape Town, previously enrolled in the now 
completed Women's Initiative for Sexual Health (WISH) study (UCT HREC267/2013) 
that aimed to determine factors affecting HIV susceptibility in the adolescent genital 
tract (100). All women consented to their samples being collected, stored, used and 
shared for research purposes. Ethics approval to conduct this study was obtained from 
UCT’s Human Research Ethics Committee (HREC202/2018). To obtain pure isolates, 
vaginal samples were streaked as to obtain single colonies on plates of nalidixic acid-
supplemented Columbia blood agar (Biomérieux, Marcy-l'Étoile, France) for G. vaginalis 
and MRS (Sigma-Aldrich, Missouri, United States of America) agar (BD Biosciences, 
New Jersey, United States of America) for L. gasseri and grown anaerobically (using 
Oxoid AnaeroGen Sachet, Thermo Fisher Scientific, Massachusetts, United States of 
America) for 48 h at 37°C. Colonies were picked and regrown on Columbia blood agar 
(Biomérieux, Marcy-l'Étoile, France) if confirmed to be G. vaginalis or L. gasseri by 
MALDI-TOF (Bruker Daltonics, CHU de Montpellier, France). The isolates were stored 
at -80°C for the duration of this study in 20% (v/v) glycerol (Sigma-Aldrich, Missouri, 
United States of America) 5% (v/v) horse blood (Primate Unit and Delft Animal Center, 
Cape Town, South Africa)-supplemented Schaedler medium (Oxiod, Hampshire, United 




2.2 DNA extraction  
Isolates of G. vaginalis from -80°C freezer stocks were grown anaerobically in 5% (v/v) 
horse blood-supplemented Schaedler (5%SB) agar plates for 48 h at 37°C. DNA was 
extracted from bacterial colonies using InstaGene matrix (Bio-Rad, California, United 
States of America) according to the manufacturer’s instructions. Briefly, bacterial cells 
were washed in phosphate buffered saline (PBS, Sigma-Aldrich, Missouri, United States 
of America), resuspended in 200 μl InstaGene matrix, incubated for 30 min at 56°C and 
then 100°C for 8 min before being stored at -20°C. The supernatant containing 
extracted DNA was used for PCR of the cpn60 gene (section 2.3) and sialidase gene 
(section 2.4). 
 
2.3 cpn60 PCR 
To genotype G. vaginalis isolates, a 552bp DNA region of the cpn60 housekeeping 
gene, which was previously used to genotype G. vaginalis isolates (27, 72), was 
amplified through PCR and sequenced. cpn60 PCR reactions were carried out using 
forward primer H729 5’-CGCCAGGGTTTTCCCAGTCACGACGAIIIIGCIGGIGAYGGIA-
CIACIAC-3’ and reverse primer H730 5’-AGCGGATAACAATTTCACACAGGAYKIYKIT-
CICCRAAICCIGGIGCYTT-3’, from a previous study (72). Amplifications were done in a 
50 μl reaction mix made up of 20 μl extracted DNA, 250 μM PCR grade nucleotide mix, 
800 nM of each primer, PCR reaction buffer (2.5 mM MgCl2, 50 mM KCl, 10 mM 
Tris.HCl, pH 8.3) and 2.5 units of Taq DNA polymerase (Roche, Basel, Switzerland). 
The PCR reactions ran for 3 min at 94°C, followed by 40 cycles of 30 sec at 94°C, 1 min 
at 52°C and 60 sec at 72°C, with a final extension time of 10 min at 72°C.  The G. 
vaginalis isolates, with a detectable ~600bp DNA band visible on 2% (w/v) agarose gel 
(Eurogentec, Liège, Belgium), were sequenced using Sanger sequencing (Genoscreen, 
Lille, France) with M13 (-47) forward and M13 (-48) reverse sequencing primers 
(underlined sequences). G. vaginalis isolates with poor quality reads were re-
sequenced using Sanger sequencing (Eurofins Genomics, Ebersberg, Germany) with 
the same primers. 
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2.4 Sialidase PCR 
To screen G. vaginalis isolates for the presence of the sialidase gene, a sialidase 682bp 
DNA region was amplified using forward primer sia1-F 5’-ATGGAACGTCGTTCAACGA-
AG-3’ and reverse primer sia1-R 5’-GATACGCGTTTTATGTCTCTTGC-3’, from a 
previous study (71). Amplifications were done in 25 μl reaction mix made up of 10 μl 
extracted DNA, 200 μM PCR grade nucleotide mix, 200 nM of each primer, PCR 
reaction buffer mix (2.5 mM MgCl2, 50 mM KCl, 10 mM Tris.HCl, pH 8.3) and 1.25 units 
of Taq DNA polymerase. The reactions ran for 3 min at 94°C, followed by 28 cycles of 
30 sec at 94°C, 30 sec at 52°C and 50 sec at 72°C, with a final extension time of 10 min 
at 72°C. The G. vaginalis isolates with a detectable ~700bp DNA band visible on 2% 
(w/v) agarose gel were sequenced using Sanger sequencing (Genoscreen, Lille, 
France).  
 
2.5 Phylogenetic analysis 
All phylogenetic analyses were performed using Geneious software (version 10.2.3, 
Biomatters). A cpn60 phylogenetic tree was constructed with 90 sequences obtained 
from isolates in this study, as well as five sequences from the online database, cpnDB 
(cpnDB_nr; www.cpndb.ca), of which four sequences were used to delineate the four 
subgroups of G. vaginalis that were previously described (72), while Bifidobacterium 
asteroides PRL2011 was used to root the tree. A sialidase phylogenetic tree was 
constructed with 75 sequences obtained from isolates in this study, while a 
Bifidobacterium bifidum ATCC 15696 571bp sialidase gene region from NCBI was used 
to root the tree. Sequences were aligned using Geneious pairwise aligner with a 51% 
similarity cost matrix; the genetic distance model was calculated using HKY and the tree 





2.6 Sialidase activity quantification 
Since sialidase gene presence is not always predictive of sialidase gene activity (27), 
the sialidase activity of all 109 G. vaginalis isolates was quantified. Isolates of G. 
vaginalis from -80°C freezer stocks were grown anaerobically on 5%SB agar plates for 
48 h at 37°C. A loopful (10 μl) of bacteria were grown anaerobically in 1.5 ml 0.1% (w/v) 
starch (Sigma-Aldrich, Missouri, United States of America), 0.5% (w/v) yeast (BD 
Biosciences, New Jersey, United States of America)-supplemented brain heart infusion 
(sBHI, Sigma-Aldrich, Missouri, United States of America) medium for 48 h at 37°C.  
The optical density at a wavelength of 600 nm (OD600nm) of bacteria was measured 
using a cell density meter (model WPA CO8000, Biochrom, Cambridge, United 
Kingdom) and 50 μl of the culture was added to triplicate wells of a 96 well black flat 
bottom plate (Sigma-Aldrich, Missouri, United States of America) containing 100 μl of 
460 μM 2′-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium salt hydrate 
(4MUsia, Sigma-Aldrich, Missouri, United States of America) in 0.1M sodium acetate 
(Sigma-Aldrich, Missouri, United States of America), pH 5.5. Sialidase activity was 
quantified by measuring fluorescence (excitation at 365 nm and emission at 440 nm), 
one well at a time, reading the plate 20 times within a total of 45 min using the Glomax 
Multi Detection system (Promega, Wisconsin, United States of America). The rate of 
substrate conversion was reported as relative fluorescence units (RFU), which were 
obtained by averaging out the 20 readings of each triplicate and adjusting for cell 
concentration. 
 
2.7 Biofilm formation quantification  
As biofilm is the hallmark trait of BV (44, 63, 84), the amount of biofilm formed by G. 
vaginalis isolates was quantified. Isolates of G. vaginalis from -80°C freezer stocks were 
grown anaerobically on 5%SB agar plates for 48 h at 37°C. A loopful of bacteria were 
grown anaerobically in 1.5 ml 5%SB for 48 h at 37°C. After standardizing the bacteria to 
an OD600nm of 1, 200 μl of the cultures were distributed into 8 replicate wells of a 96 
well round bottom plate (Corning, New York, United States of America) and grown 
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anaerobically for 48 h at 37°C. Planktonic cells were carefully pipetted out and the 
biofilm was stained for 15 min in 225 μl 1% (v/v) crystal violet dye (Sigma-Aldrich, 
Missouri, United States of America), which was diluted in distilled water. Plates were 
washed three times by carefully adding distillated water, at a low water pressure, to the 
wells, inverting the plate and placing it firmly above an empty pipette box, gently moving 
it from left to right as to remove the water, while preventing loss of biofilm, and finally, 
gently blotting the plate dry against a paper towel. Crystal violet dye-bound biofilm was 
dissolved in 200 μl of 30% (v/v) acetic acid (Sigma-Aldrich, Missouri, United States of 
America), which was diluted in distilled water. Biofilm was quantified at OD550nm using 
a VersaMax microplate reader and its SoftMax PRO software (version 5, Molecular 
Devices, California, United States of America). 
 
2.8 Antibiotic susceptibility testing 
The susceptibility of G. vaginalis isolates to antibiotics used to treat BV, including 
metronidazole, clindamycin, augmentin and moxifloxacin, was tested. Isolates of G. 
vaginalis from -80°C freezer stocks were grown anaerobically on 5%SB agar plates for 
48 h at 37°C. The turbidity of the bacterial cultures were standardized to McFarland unit  
of 1 in saline before being streaked to form a lawn (merged bacterial colonies) on 5% 
horse blood-supplemented Brucella agar plates (BD Biosciences, New Jersey, United 
States of America). Bacteria were grown anaerobically for 48 h at 37°C, in the presence 
of metronidazole, clindamycin, augmentin and moxifloxacin antibiotic minimum inhibitory 
concentration (MIC) test strips (Liofilchem, Roseto degli Abruzzi, Italy) impregnated with 
a concentration gradient of 0.016-256 μg/ml of the various antibiotics. The MIC was 
determined as being the lowest antibiotic concentration along the strip inhibiting G. 
vaginalis growth. 
 
2.9 G. vaginalis prophage induction 
Since the presence of prophage sequences in G. vaginalis genomes has been reported 
(59, 96), it was hypothesized that L. gasseri supernatant could induce prophages of G. 
34 
 
vaginalis, as L. gasseri is known to inhibit G. vaginalis growth (98) and produce 
hydrogen peroxide, a prophage-inducing agent (97). The ability of L. gasseri 
supernatant to induce prophages of G. vaginalis was thus tested. The L. gasseri 
supernatant was obtained from an overnight culture of L. gasseri in 0%SB that was 
centrifuged at 3500xg for 10 min before sterile-filtering (0.2 μm, GVS, Sanford, United 
States of America) the supernatant. Furthermore, UV-C radiation at 254 nm (TUV TL 
8W Mini lamp, Phillips, Amsterdam, Netherlands), mitomycin C (Sigma-Aldrich, 
Missouri, United States of America) and ciprofloxacin (Sigma-Aldrich, Missouri, United 
States of America) were tested for their ability to induce prophages of G. vaginalis 
isolates, as they are commonly used to induce prophages of other bacteria (99). 
Prophage-inducing agents are commonly introduced to growing bacterial cultures during 
early log phase as this maximizes the chances of prophage induction (101). To this end, 
the growth kinetics of G. vaginalis needed to be determined.  
 
2.9.1 Growth kinetics of G. vaginalis  
Isolates of G. vaginalis from -80°C freezer stocks were grown anaerobically on 5%SB 
agar plates for 48 h at 37°C. A loopful of bacteria were grown anaerobically in 1.5 ml 
5%SB for 48 h at 37°C. Cultures were standardized to an OD600nm of 0.1, in duplicate, 
in 15 ml or 50 ml 5%SB or Schaedler medium without blood (0%SB) and grown 
anaerobically for 48 h at 37°C. The growth of G. vaginalis was monitored by measuring 
the OD600nm of 100 μl of the growing cultures at 9 time points.  
 
2.9.2 Prophage induction using L. gasseri supernatant 
To optimize experimental conditions for prophage induction of G. vaginalis isolates 
using L. gasseri supernatant, dilutions of L. gasseri supernatant (0-50%) were 
performed on 9 h log-phase (OD600nm 0.7, range 0.5-0.8) G. vaginalis cultures that 
had started growing from an OD600nm of 0.1 in 0%SB. As a control, the same dilutions 
were performed using only 0%SB. Bacteria were grown anaerobically, in duplicate 150 
μl volumes, in 96 well round bottom plates. Growth of G. vaginalis was monitored until 
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18 h after the addition of the L. gasseri supernatant by removing 50 μl of the growing 
culture at various time points to measure its OD600nm. In a subsequent experiment to 
induce prophages in a larger volume, G. vaginalis were subcultured in 50 ml 0%SB for 9 
h (OD600nm of 0.34, range 0.3-0.4) before 25 ml L. gasseri supernatant was added to 
25 ml of this culture. As a control, 25 ml log-phase cultures of G. vaginalis were grown 
with 25 ml Schaedler medium. Growth of G. vaginalis was quantified at 6, 12 and 20 h 
after the addition of the L. gasseri supernatant by removing 100 μl of the growing culture 
to measure its OD600nm. To determine the viability of the isolates grown in the 
presence of 50% L. gasseri supernatant, after the isolates had grown for a total of 29 h, 
a cotton swab was inoculated with the various cultures, streaked to form a lawn on 
0%SB agar plates and incubated for 48 h at 37°C. 
 
2.9.3 Prophage induction using UV radiation  
To optimize experimental conditions for prophage induction of G. vaginalis isolates 
using UV radiation, 1.5 ml of 9 h log-phase bacteria in 0%SB were centrifuged at 589xg 
for 5min, 1.2 ml of the supernatant was discarded, 300 l of the log-phase G. vaginalis 
isolates were streaked on 0%SB agar plate and placed under UV radiation for 10-60 
sec before collecting the cells with 1.5 ml 0%SB. A control of G. vaginalis isolates not 
irradiated with UV was included. Bacteria were grown anaerobically, in duplicate 150 μl 
volumes, in 96 well round bottom plates. Growth of G. vaginalis was quantified at 12 h 
and 18 h by removing 50 μl of the growing culture to measure its OD600nm.  
 
2.9.4 Prophage induction using mitomycin C 
For prophage induction using mitomycin C, G. vaginalis isolates were subcultured in 50 
ml 5%SB for 16-18 h (OD600nm 4, range 3.5-4.5), upon where 0.5 μg/ml mitomycin C 
(which was diluted in 0.1mm sterile-filtered water, Sigma Aldrich, Missouri, United 
States of America) was added to the growing cultures. As a control, G. vaginalis isolates 
were subcultured in 50 ml 5%SB without mitomycin C. Growth of G. vaginalis was 
quantified at 24 h and 36 h after inoculation by removing 100 μl of the growing cultures 
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to measure their OD600nm. To determine the viability of the isolates grown in the 
presence of 0.5 μg/ml mitomycin C, after the isolates had grown for a total of 36 h, a 
cotton swab was inoculated with the various cultures, streaked to form a lawn on 5%SB 
agar plates and incubated for 48 h at 37°C. In a subsequent experiment to optimize 
experimental conditions for prophage induction using mitomycin C, two-fold serial 
dilutions of mitomycin C (0.5-16 μg/ml) were performed on 9 h log-phase G. vaginalis 
cultures (OD600nm 0.7, range 0.5-0.8) that had started growing from an OD600nm of 
0.1 in 0%SB. As a control, G. vaginalis isolates were subcultured without mitomycin C. 
Growth of G. vaginalis was quantified 12 h and 18 h after the addition of mitomycin C, 
by removing 50 μl of the growing cultures to measure their OD600nm. 
 
2.9.5 Prophage induction using ciprofloxacin 
To optimize experimental conditions for prophage induction of G. vaginalis isolates 
using ciprofloxacin, two-fold serial dilutions of ciprofloxacin [0.06-20.5-16 μg/ml, which 
was diluted in 0.1M HCl (Sigma-Aldrich, Missouri, United States of America)] were 
performed on 9 h log-phase G. vaginalis cultures (OD600nm 0.7, range 0.5-0.8) that 
had started growing from an OD600nm of 0.1 in 0%SB. As a control, G. vaginalis 
isolates were subcultured without ciprofloxacin. Growth of G. vaginalis was quantified 
12 h and 18 h after the addition of ciprofloxacin, by removing 50 μl of the growing 
culture to measure its OD600nm. In a subsequent experiment to induce prophages in a 
larger volume, G. vaginalis were subcultured in 15 ml 0%SB for 12 h (OD600nm of 0.6, 
range 0.5-0.7), upon where 2 μg/ml ciprofloxacin was added to the growing cultures. A 
control of growing G. vaginalis cultures without ciprofloxacin was included. Growth of G. 
vaginalis was quantified at 12, 24 and 36 h after the addition of ciprofloxacin, by 
removing 100 μl of the growing culture to measure its OD600nm. To determine the 
viability of the isolates grown in the presence of 2 μg/ml ciprofloxacin, after the isolates 
had grown for a total of 48 h, a cotton swab was inoculated with the various cultures, 





2.9.6 Transmission electron microscopy of G. vaginalis phages 
To visualize temperate phages following prophage induction, G. vaginalis supernatants 
were purified of bacterial cells and observed using transmission electron microscopy 
(TEM). A volume of 15 ml of sample was centrifuged at 3500xg for 10 min at 4°C to 
remove bacteria. The supernatant was treated with 10% (v/v) chloroform (Sigma-
Aldrich, Missouri, United States of America) for 15 min to kill residual bacteria before 
centrifuging the supernatant, as before, to remove any remaining bacterial debris. 
Supernatants were sterile-filtered (0.2 μm) to further purify any phages that were 
present. A total of 12 ml per sample was centrifuged at 20 800xg for 60 min at 4°C 
before washing the pellet twice in sterile-filtered (0.2 μm) 0.1 M NH4-acetate (Sigma-
Aldrich, Missouri, United States of America), pH 7, which was diluted in distilled water. 
The pellet was resuspended in 50 μl 0.1 M NH4-acetate. A volume of 10 μl of sample 
was incubated for 10 min on an ionized TEM grid (Agar Scientific, London, United 
Kingdom) and stained with 10 μl 2% (w/v) uranyl acetate (SPI Supplies, Pennsylvania, 
United States of America) before being analyzed under TEM (using an FEI Tecnai T20 
TEM, Eindhoven, Netherlands), with the help of TEM specialist, Mr Mohammed A. Jaffer 
at the Aaron Klug Centre for Imaging and Analysis, University of Cape Town. 
 
2.10 Statistical analysis 
Pie charts were constructed using Microsoft Excel (Microsoft Corporation). All graphs 
and statistical analyses were performed using Prism, version 5 (GraphPad). 
Nonparametric, unpaired Mann-Whitney U tests and Fischer’s exact tests were used to 




Chapter 3: Results 
 
Recent evidence suggests that there is significant heterogeneity within the species of G. 
vaginalis and that not all genotypes of G. vaginalis may be involved in BV (27, 57, 67, 
72). Thus, the genotypic and phenotypic diversity of 109 vaginal G. vaginalis isolates 
(kindly provided by Dr Rémy Froissart, Institut de Recherche pour le Développement, 
France) were characterized in this study. Genotypic diversity was investigated through 
cpn60 phylogenetic analysis (section 3.1), while phenotypic diversity was investigated 
through evaluating sialidase activity (section 3.2), biofilm formation (section 3.3) and 
susceptibility to antibiotics used to treat BV (section 3.4). The presence of prophages in 
a panel of G. vaginalis isolates was also investigated (sections 3.5). Of the 109 G. 
vaginalis isolates used in this study, 75 (69%) were from BV-positive women (Nugent 7-
10), 20 (18%) were from BV-intermediate women (Nugent 4-6) and 14 (13%) were from 
BV-negative women (Nugent 0-3, Figure 3.1 B). 
 
3.1 Genotyping G. vaginalis isolates using cpn60 sequence analysis 
Previous whole genome sequence analysis as well as sequence analysis of a 552bp 
region of the cpn60 housekeeping gene revealed that G. vaginalis isolates cluster in 
four subgroups, termed subgroups A-D (27, 57, 72). To genotype the 109 G. vaginalis 
isolates used in this study, cpn60 phylogenetic analysis was performed (Figure 3.1 A). 
Included in the phylogenetic analysis were four reference sequences (obtained from 
cpnDB_nr; www.cpndb.ca), each previously determined to cluster in one of the four 
subgroups of G. vaginalis (72), including N143 from subgroup A, N153 from subgroup 
B, ATCC 14019 from subgroup C and 101 from subgroup D. Of the 109 isolates used in 
this study, 94 (86%) produced PCR products of the expected size (~600bp) and were 
sequenced. Of these, 90/94 (96%) produced high quality reads of sufficient size for 




cpn60 sequences of the 90 G. vaginalis isolates clustered into four subgroups, with 13 
subgroup A (14%), 17 subgroup B (19%), 58 subgroup C (64%) and 2 subgroup D (2%) 
isolates being detected in this collection (Figure 3.1 A). Subgroups A, B and C included 
isolates from women of all BV states, while subgroup D included isolates from BV-
positive women only (Figure 3.1 B). Isolates from BV-positive women were the most 
prevalent across all subgroups. In summary, isolates from this study cluster in four 
subgroups, with subgroup D isolates being the least prevalent, while the majority of 
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Figure 3.1: cpn60-based phylogenetic analysis of G. vaginalis isolates. (A) cpn60 
sequences of the 90 isolates used in this study cluster in four clades (subgroups). Four 
sequences from a publically available cpn60 database (cpnDB_nr, www.cpndb.ca) were 
included in the analysis to delineate subgroup A (N143, red), B (N153, blue), C (ATCC 14019, 
green), and D (101, gold) G. vaginalis clades, described in a previous study (72), while 
Bifidobacterium asteroides PRL2011 (also from cpnDB_nr) was used to root the tree. The tree 
was generated using the neighbor-joining method and 100 bootstrap replicates on Geneious 
(version 10.2.3, Biomatters). Super-imposed is a vertical bar indicating BV status, 
corresponding to the colour code in B. (B) Frequency of G. vaginalis isolates from BV-negative 
(Nugent 0-3), BV-intermediate (Nugent 4-6) and BV-positive women (Nugent 7-10). The first pie 
chart (Total) characterizes the entire collection of 109 G. vaginalis isolates while the rest of the 
pie charts characterize a subset (90/109) of the collection that is made up of isolates which 
cpn60 was detected by PCR and sequenced. Number of isolates is indicated in brackets. 
 
3.2.1 Sialidase gene presence in G. vaginalis isolates  
G. vaginalis is known to produce sialidase, a mucolytic enzyme that cleaves sialic acids 
that make up the protective mucus layer lining the vaginal epithelium (80). Sialidase 
activity is detected in 69-84% of vaginal secretions from BV-positive women (27-29), in 
contrast to only 3.2-6% of vaginal secretions from BV-negative women (29, 30). It was 
hypothesized that during BV, sialidase breaks down protective vaginal mucus, allowing 
pathogenic bacteria to adhere to vaginal epithelium and form biofilms (81). It was 
recently shown that not all subgroups of G. vaginalis harbor the sialidase gene (27). To 
screen for the presence of the sialidase gene in G. vaginalis isolates in this study, PCR 
was carried using G. vaginalis sialidase-specific primers from previous studies (71, 72). 
Of the 109 G. vaginalis isolates used in this study, 75 produced PCR products of the 
expected size (~700bp) and were sequenced. All 75 isolates produced high quality 
reads of sufficient size for alignment and phylogenetic analysis.  
 
The sialidase gene was detected at similar frequencies in 13/17 (76%) subgroup B and 
53/58 (91%) subgroup C isolates (p = 0.2, Fischer’s exact test), but was not detected in 
any of 13 subgroup A or 2 subgroup D isolates (Figure 3.2 A). Sialidase sequences of 
subgroup C isolates clustered together, separately from sialidase sequences of 
subgroup B isolates (Figure 3.2 C). The sialidase gene was detected at similar 
frequencies in G. vaginalis isolates from BV-negative (79%, 11/14), BV-intermediate 
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(50%, 10/20) and BV-positive (72%, 54/75) women (p > 0.05 for all comparisons, 
Fischer’s exact tests, Figure 3.2 B). In summary, the sialidase gene was not detected in 
subgroup A and D isolates, was detected in the majority of subgroup B and C isolates 
and was detected at similar frequencies in isolates from women of different BV states. 
 
3.2.2 Quantifying sialidase activity of G. vaginalis isolates 
It was previously shown that sialidase gene presence is not predictive of sialidase 
enzymatic activity, particularly for G. vaginalis subgroup C isolates where only 9% (3/35) 
of sialidase-PCR-positive isolates had detectable sialidase activity (27). The sialidase 
activity of this collection of 109 G. vaginalis isolates was measured by quantifying the 
rate of hydrolysis of a fluorescent sialidase substrate. Sialidase activity was detected in 
only 36% (27/75) of sialidase-PCR-positive isolates (Figure 3.2 B). There was no 
significant difference in frequency of G. vaginalis isolates with detectable sialidase 
activity between subgroup B (41%, 7/17) and C (31%, 18/58) isolates (p = 0.56; 
Fischer’s exact test, Figure 3.2 A). None of the subgroup A or D isolates had detectable 
sialidase activity, consistent with the lack of sialidase gene detection in these 
subgroups. Sialidase activity was detected at similar frequencies in G. vaginalis isolates 
from BV-negative (21%, 3/14), BV-intermediate (20%, 4/20) and BV-positive (27%, 
20/75) women (p > 0.05 for all comparisons, Fischer’s exact tests, Figure 3.2 B).  
 
As sialidase activity was not detected in the majority of isolates, there was no significant 
difference between median sialidase activity of isolates from different subgroups or from 
women with different BV states (p > 0.05 for all comparisons, Mann-Whitney U tests). 
This was true even when statistical analysis was performed only on isolates that had 
detectable sialidase activity. In summary, the detection of the sialidase gene was only 
36% predictive of sialidase activity. Additionally, sialidase activity was detected at similar 
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Figure 3.2: Sialidase gene presence and activity of G. vaginalis isolates. Screening G. 
vaginalis isolates for the detection of sialidase gene and activity from (A) different subgroups 
and (B) BV-negative (Nugent 0-3), BV-intermediate (Nugent 4-6) and BV-positive women 
(Nugent 7-10). Sialidase activity of stationary-phase G. vaginalis was measured using a 
fluorescent sialidase substrate and reported in relative fluorescence units (RFU) representing an 
average of 20 triplicate fluorescence readings per isolate, taken over 45 min and adjusted for 
cell concentration. Turkey box and whisker plots are shown. Each point represents an average 
of triplicate readings of one isolate. (C) Phylogenetic tree of 75 G. vaginalis sialidase 
sequences. Bifidobacterium bifidum ATCC 15696 from NCBI was used to root the tree. Different 
colours indicate G. vaginalis cpn60-based subgroups, with blue indicating subgroup B, green 
indicating subgroup C and black indicating cpn60 PCR-negative isolates. The tree was 
generated using the neighbor-joining method and 100 bootstrap replicates on Geneious 
(Biomatters). 
 
3.3 Quantifying biofilm formation of G. vaginalis isolates 
G. vaginalis is thought to play a critical role during BV pathogenesis by initiating the 
formation of biofilm, which subsequently allows other pathogenic bacteria to colonize 
the female genital tract, forming a polymicrobial biofilm (44). A previous qualitative study 
revealed that isolates from all subgroups of G. vaginalis are able to form biofilm; 
although, the amount of biofilm formed was not quantified (72). To quantify biofilm 
formation in this study, G. vaginalis biofilms in 96 well plates were stained with crystal 
violet dye and measured at OD550nm, as previously described (102). Biofilm formation 
of subgroup A (median 0.16, range 0.10-1.96), subgroup B (median 0.22, range 0.10-
1.75) and subgroup C isolates (median 0.15, range 0.07-2.15) was similar (p > 0.05 for 
all comparisons, Mann-Whitney U tests, Figure 3.3 A). Biofilm formation of the two 
subgroup D isolates was also measured (average 1.36, range 0.97-1.78) but could not 
be statistically compared to the other subgroups as a minimum of three values is 
required to perform a Mann-Whitney U test. Biofilm formation of isolates from BV-
negative women (median 0.30, range 0.1-1.7), BV-intermediate women (median 0.25, 
range 0.1-2.0) and BV-positive women (median 0.20, range 0.1-2.1) was similar (p > 
0.05 for all comparisons, Mann-Whitney U tests, Figure 3.3 B). Taken together, these 
data suggest that isolates from all subgroups of G. vaginalis as well as isolates from 





Figure 3.3: Biofilm formation of G. vaginalis isolates. Biofilm formation of stationary-phase 
G. vaginalis isolates was stained with crystal violet dye and measured. (A) Biofilm formation of 
G. vaginalis subgroups. (B) Biofilm formation of G. vaginalis isolates from BV-negative (Nugent 
0-3), BV-intermediate (Nugent 4-6) and BV-positive women (Nugent 7-10). Turkey box and 
whisker plots are shown. Each point represents a reading of one isolate, obtained from an 
average of three independent experiments, each with 8 replicates per isolate. 
 
3.4 Antibiotic susceptibility of G. vaginalis isolates 
As G. vaginalis plays such a central role in BV, its susceptibility to antibiotics used to 
treat BV influences treatment outcomes (87). The antibiotic susceptibility of G. vaginalis 
isolates to metronidazole and clindamycin, the first-line recommended antibiotics for the 
treatment of BV (38), was thus tested. Given the substantial amount of metronidazole 
and clindamycin BV treatment failure as well as high BV recurrence rates (6, 39), 
alternative antibiotics to treat BV are being explored, including moxifloxacin and 
augmentin, which have both demonstrated clinical efficacy in the treatment of BV (90, 
91). Thus, the antibiotic susceptibility of G. vaginalis isolates to moxifloxacin and 
augmentin was also tested. Antibiotic susceptibility was tested by growing G. vaginalis 
isolates in the presence of MIC test strips (containing 0.016-256 μg/ml of the various 
antibiotics), in a lawn, on 5% blood-supplemented Brucella agar, as recommended by 
the manufacturer. However, antibiotic susceptibility was measured for only 45/109 G. 
vaginalis isolates as the remainder of the isolates could not form a lawn on 5% blood-
supplemented Brucella agar. 
 














































Metronidazole had the highest median MIC (256 μg/ml) for the 45 tested G. vaginalis 
isolates, followed by moxifloxacin (0.25 μg/ml), clindamycin (0.094 μg/ml), and then 
augmentin (0.047 μg/ml, p < 0.0001 for all comparisons, Mann-Whitney U tests, Figure 
3.4 A). Previous studies described breakpoints for G. vaginalis resistance to 
metronidazole as 32 μg/ml (41), clindamycin as 4 μg/ml (42), moxifloxacin as 0.5 μg/ml 
(103), and augmentin as 8 μg/ml (42). Using these breakpoints for resistance, 71% 
(32/45) of isolates were resistant to metronidazole, 9% (4/45) were resistant to 
moxifloxacin, while none were resistant to clindamycin or augmentin (Figure 3.4 A). Of 
the isolates that were resistant to metronidazole, 84% (27/32) were highly resistant, as 
defined as having an MIC ≥ 256 μg/ml, the highest concentration of antibiotic along the 
MIC test strip. This level of resistance was not observed for clindamycin, moxifloxacin or 
augmentin. Metronidazole resistance was observed across all subgroups of G. 
vaginalis, while moxifloxacin resistance was only observed in subgroup C isolates 
(Figure 3.4 B). Similarly, metronidazole resistance was observed across isolates from 
women of all BV states, while moxifloxacin resistance was only observed in isolates 
from BV-positive women (Figure 3.4 C). Taken together, these data reveal that the 
majority of G. vaginalis isolates were resistant to metronidazole, the most commonly 






Figure 3.4: Antibiotic susceptibility of G. vaginalis isolates. Metronidazole, clindamycin, 
moxifloxacin and augmentin MICs of G. vaginalis isolates grown on 5% blood-supplemented 
Brucella agar were determined using MIC test strips for (A) a total of 45 G. vaginalis isolates; 
(B) 3, 6 and 33 and 1 isolate from subgroup A, B, C and D, respectively and (C) 6, 5 and 34 
isolates from BV-negative, BV-intermediate and BV-positive women, respectively. Turkey box 
and whisker plots are shown. Each point represents one isolate. Horizontal broken lines mark 
the breakpoints for G. vaginalis resistance to metronidazole (32 μg/ml), clindamycin (4 μg/ml), 
moxifloxacin (0.5 μg/ml) and augmentin (8 μg/ml), as described in previous studies (41, 42, 
103). Fischer’s exact tests (p < 0.0001) were used to test for statistical significant differences in 
frequency of resistant isolates per antibiotic. 











































































3.5 Prophage induction of G. vaginalis  
Prophage sequences have previously been found in genomes of G. vaginalis (59, 96); 
however, phages of G. vaginalis have never been isolated. L. gasseri produce hydrogen 
peroxide, a prophage-inducing agent known to inhibit G. vaginalis growth (97, 98). It 
was thus hypothesized hydrogen peroxide released by L. gasseri inhibits G. vaginalis 
growth by inducing prophages of G. vaginalis. The ability of L. gasseri culture 
supernatant to induce prophages of G. vaginalis was thus tested. Additionally, 
mitomycin C, ciprofloxacin and UV radiation are commonly used to induce prophages of 
other bacteria (99, 104); thus, these prophage-inducing agents were tested for their use 
as positive controls in the induction of G. vaginalis prophages 
 
3.5.1 Optimizing experimental conditions for prophage induction of G. vaginalis 
In order to induce prophages of G. vaginalis, isolates were initially grown in 5% blood-
supplemented Schaedler medium, in the presence or absence of prophage-inducing 
agents. However, mitomycin C, ciprofloxacin and L. gasseri supernatant appeared to 
cause red blood cells lysis as they changed the colour of the blood-supplemented 
medium from red to yellow. It was thus necessary to grow G. vaginalis isolates in 
Schaedler medium without blood in subsequent prophage induction experiments. In our 
laboratory, prophage induction experiments are often conducted using 50 ml culture 
volumes as this volume is large enough to yield enough phage particles to observe 
under TEM and perform phage DNA extraction for whole genome sequencing. 
However, only 15 ml is required to yield enough phage particles to observe under TEM. 
It was thus decided that the prophage induction optimization experiments would be 
conducted using 15 ml culture volumes until productive prophage induction was 
suspected and phage DNA needed to be extracted. 
 
Because prophage-inducing agents are commonly added to early log-phase bacterial 
cultures (101), the growth kinetics of G. vaginalis needed to be determined. To do this, 
three G. vaginalis isolates, 3G7 (red) from subgroup A, 3H8 (blue) from subgroup B and 
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3B3 (green) from subgroup C, were standardized to an OD600nm of 0.1 in 5% blood-
supplemented Schaedler medium (5%SB) or Schaedler medium without blood (0%SB) 
and their growth was monitored over 48 h. At stationary phase, growth of all three G. 
vaginalis isolates was two times higher in the presence (Figure 3.5 A) than in the 
absence (Figure 3.5 B) of blood. Growth kinetics of G. vaginalis did not seem to be 
affected by volume as, when grown in the absence of blood, growth kinetics of G. 
vaginalis were similar in 50 ml (Figure 3.5 B) and 15 ml (Figure 3.5 C) culture volumes. 
In the presence of blood, G. vaginalis isolates had a lag phase of 7 h, grew 
exponentially between 7-18 h, slowing down at 18-36 hours, before reaching stationary 
phase after 36-48 h (Figure 3.5 A). In contrast, the absence of blood, G. vaginalis 
growth was more modest during the exponential phase (7-18 h), after which no further 
growth was evident between 18-48 h (Figure 3.5 B-C). It was concluded that, even 
though G. vaginalis isolates grew to higher cell density in the presence of blood, isolates 
grew satisfactorily in the absence of blood. Thus, isolates were grown in the absence of 





Figure 3.5: Growth kinetics of G. vaginalis isolates. G. vaginalis standardized to an 
OD600nm of 0.1 were subcultured in Schaedler medium with or without blood for 48 h. Growth 
kinetics of G. vaginalis in (A) 50 ml 5%SB, (B) 50 ml 0%SB and (C) 15 ml 0%SB were 
measured at 9 time points for three isolates from subgroup A (3G7, red), B (3H8, blue) and C 
(3B3, green). Graphs represent an average of two independent experiments. Error bars 
represent SEM.  
 
3.5.2 G. vaginalis prophage induction using L. gasseri supernatant 
The culture supernatant of one L. gasseri isolate, known to produce ~10µM hydrogen 
peroxide (determined by Ms Anna Happel; PhD candidate, Division of Medical Virology, 
University of Cape Town), was tested for its ability to induce prophages of G. vaginalis. 
L. gasseri supernatant at a final concentration of 50% (v/v) inhibited G. vaginalis growth 





















































(79% average, range, 68-88% at 12 h; 74% average, range 73-75% at 18 h) but didn’t 
affect G. vaginalis growth at lower concentrations of 0.03-33% (Figure 3.6 A-B).  
 
Inhibition of G. vaginalis growth in the presence of 50% L. gasseri supernatant may 
have been due to G. vaginalis being most dilute in this dilution (50% G. vaginalis) 
compared to the other dilutions (67%-100% G. vaginalis), thus resulting in G. vaginalis 
being unable to grow as high as in the other dilutions. To investigate this, the 
experiment was repeated using 50% L. gasseri supernatant as well as 50% Schaedler 
medium control. As there was no reduction in G. vaginalis growth in the 50% Schaedler 
medium control (Figure 3.6 C), it was concluded that the reduction in G. vaginalis 
growth in the 50% L. gasseri supernatant dilution was due to L. gasseri supernatant 
contents, possibly hydrogen peroxide. 
 
Since the 50% L. gasseri supernatant concentration was the most potent G. vaginalis-
inhibiting concentration, the ability of 50% L. gasseri supernatant to induce prophages 
of G. vaginalis was tested using larger 50 ml culture volumes as to potentially increase 
the number of any present phage particles in order to characterize them under TEM. 
Growth of log-phase cultures of G. vaginalis was inhibited by the presence of 50% L. 
gasseri supernatant, while growth of log-phase cultures of G. vaginalis was unaffected 
by the presence of 50% Schaedler medium (Figure 3.6 D). All three G. vaginalis 
isolates grown in the presence of 50% L. gasseri supernatant failed to grow when 
subcultured on 0%SB agar; in contrast, all isolates grown in the presence of 50% 
Schaedler medium grew (data not shown). TEM analysis did not reveal the presence of 
phages in any of the log-phase cultures of G. vaginalis grown in the presence of 50% L. 
gasseri supernatant. 
 
To successfully induce prophages, prophage-inducing agents need to be used at 
concentrations that are high enough to induce prophages but are sub-lethal to the 
bacterial host (101). The observation that G. vaginalis did not grow between 12 and 18 
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h after log phase in the 50% L. gasseri supernatant dilution (Figure 3.6 A-B) suggests 
that this concentration of L. gasseri supernatant was too high to allow G. vaginalis 
growth. It was also observed that 33% L. gasseri supernatant was too low to decrease 
G. vaginalis growth, as its growth was similar to the 0% L. gasseri supernatant control 
(Figure 3.6 A-B). It was thus hypothesized that there could exist a concentration of L. 
gasseri supernatant between 33-50% that would be high enough to induce prophages 
but not too high as to inhibit G. vaginalis growth. Additionally, since growth was 
monitored for the first time at 6 h after the introduction of L. gasseri supernatant (Figure 
3.6 D), it is possible that G. vaginalis growth peaked and decreased between 0-6 h, 
leading to the false conclusion that G. vaginalis did not grow between the first 6 h after 
the introduction of L. gasseri supernatant. To address both concerns, several dilutions of 
L. gasseri supernatant (ranging between 33-50%) were introduced to log-phase cultures 
of G. vaginalis and growth was monitored after 2, 4, 6, 12 and 18 h. G. vaginalis steadily 
increased in growth from 2-18 h at all tested concentrations of L. gasseri supernatant 
(Figure 3.6 E), albeit at a slower rate than the 0% L. gasseri supernatant control 
(Figure 3.6 F). From 6 h after the introduction of L. gasseri supernatant, there was a 
trend of higher G. vaginalis growth with decreasing L. gasseri supernatant concentration 
(Figure 3.6 E). There was no difference in growth kinetics of G. vaginalis at all time 
points in all Schaedler medium control dilutions (50-33%) compared to the 0% 
Schaedler medium (100% G. vaginalis) control (Figure 3.6 F). Altogether, these data 
suggest that L. gasseri supernatant did not induce prophages of G. vaginalis isolates 
















































































































































































































































































Figure 3.6: Optimizing experimental conditions for G. vaginalis prophage induction using 
L. gasseri supernatant. Growth of three G. vaginalis isolates, 3G7 (red) from subgroup A, 3H8 
(blue) from subgroup B and 3B3 (green) from subgroup C, in the presence of 0.03-50% L. 
gasseri supernatant was measured after (A) 12 h and (B) 18 h. In a subsequent experiment, (B) 
growth of G. vaginalis isolates in the presence of 50% L. gasseri supernatant or 50% Schaedler 
medium control was measured after 18 h. (D) Growth kinetics of G. vaginalis isolates, in the 
presence (squares) or absence (circles) of 50% L. gasseri supernatant, was monitored over 29 
h. A volume of 25 ml L. gasseri supernatant was introduced to 25 ml G. vaginalis cultures at log-
phase (black arrow). In a subsequent experiment, growth kinetics of three G. vaginalis isolates 
was monitored for 2-18 h after the introduction of 33-50% (E) L. gasseri supernatant or (F) 
Schaedler medium. In all experiments, L. gasseri supernatant was introduced to log-phase (9 h, 
OD600nm 0.3-0.4) cultures of G. vaginalis and grown in 150-500 μl culture volumes in 
Schaedler medium unless otherwise stated. Error bars represent SEM of duplicate cultures.  
 
3.5.3 G. vaginalis prophage induction using UV radiation 
UV radiation is known to be potent inducer of prophages of other bacteria (101); thus, 
its ability to induce prophages of G. vaginalis isolates was tested. Log-phase cultures of 
three G. vaginalis isolates were irradiated with UV light at 254 nm for 10-60s. There 
appeared to be no difference in growth of UV-irradiated isolates compared to non-
irradiated controls at all tested durations, both at 12 h and 18 h after UV irradiation 
(Figure 3.7 A-B), suggesting that G. vaginalis isolates were not sensitive to UV 
radiation and that G. vaginalis prophages could not be induced under the tested 
experimental conditions.  
 
Figure 3.7: Optimizing experimental conditions for G. vaginalis prophage induction using 
UV radiation. Three G. vaginalis isolates, 3G7 (red) from subgroup A, 3H8 (blue) from 
subgroup B and 3B3 (green) from subgroup C, cultured in 150 μl 0%SB, were irradiated with UV 
light at 254 nm for 10-60s during log phase (9 h, OD600nm 0.3-0.4). Growth was measured at 

































































































3.5.4 G. vaginalis prophage induction using mitomycin C 
Mitomycin C is one of the most commonly used prophage-inducing agents (101), having 
recently induced prophages of Bifidobacterium species (105), the closest relatives of G. 
vaginalis (106). Initially, 0.5 μg/ml mitomycin C was tested for its ability to induce 
prophages of G. vaginalis in 50 ml 5%SB, as this is the most commonly used mitomycin 
C concentration to induce prophages of other bacteria in our laboratory. Based on 
optical density measurements, growth kinetics of all three isolates grown in the 
presence of 0.5 μg/ml mitomycin C were similar to growth kinetics of isolates grown in 
the absence of mitomycin C (Figure 3.8 A). All three isolates grown in the presence of 
0.5 μg/ml mitomycin C failed to grow when subcultured on 5%SB agar; in contrast, 
control isolates grown in the absence of mitomycin C grew (data not shown). TEM 
analysis did not reveal the presence of phages in any of the isolates grown in the 
presence of 0.5 μg/ml mitomycin C.  
 
It was hypothesized that this concentration of mitomycin C (0.5 μg/ml) may have been 
too low to induce prophages of G. vaginalis isolates. To optimize experimental 
conditions for prophage induction of G. vaginalis isolates using mitomycin C, higher 
concentrations of mitomycin C (two-fold dilution series, 0.5-16 μg/ml) were tested for 
their ability to induce prophages of G. vaginalis isolates in 150 μl 0%SB. All isolates 
displayed a general trend of decreasing growth with increasing mitomycin C 
concentrations (Figure 3.8 B-C). Although, this was likely not due to prophage 
induction, as all isolates continued to grow between 12 h and 18 h. As with G. vaginalis 
isolates grown in the presence 0.5 μg/ml mitomycin C, TEM analysis of G. vaginalis 
isolates grown in the presence of 8 μg/ml mitomycin C in 15 ml 0%SB did not reveal the 




Figure 3.8: Optimizing experimental conditions for G. vaginalis prophage induction using 
mitomycin C. Three G. vaginalis isolates, 3G7 (red) from subgroup A, 3H8 (blue) from 
subgroup B and 3B3 (green) from subgroup C were cultured in (A) 50 ml 5%SB, in the presence 
(squares) and absence (circles) of 0.5 μg/ml mitomycin C introduced at log phase (dotted line, 
16-18 h, OD600nm 4, range 3.5-4.5) and growth was monitored over 36 h. In a subsequent 
experiment, growth of three G. vaginalis isolates, cultured in 150 μl 0%SB was measured at (B) 
12 h and (C) 18 h after the introduction of 0.5-16 μg/ml mitomycin C during log phase (9 h, 
OD600nm 0.3-0.4). Error bars represent SEM of duplicate cultures.  
 
3.5.5 G. vaginalis prophage induction using ciprofloxacin 
Ciprofloxacin is a fluoroquinolone, a family of antibiotics commonly used to induce 
prophages of other bacteria (101). To optimize experimental conditions for prophage 
induction of G. vaginalis isolates using ciprofloxacin, various concentrations of 
ciprofloxacin (two-fold dilution series, 0.06-2 μg/ml) were tested for their ability to induce 
prophages of G. vaginalis isolates in 150 μl 0%SB. Compared to lower concentrations, 
2 μg/ml ciprofloxacin was the most potent G. vaginalis-inhibiting concentration (Figure 
3.9 A-B). Therefore, the ability of 2 μg/ml ciprofloxacin to induce prophages of G. 
vaginalis was tested using larger 15 ml culture volumes.  
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In the presence of ciprofloxacin, G. vaginalis isolates grew slower and to a lower cell 
density compared to control isolates grown in the absence of ciprofloxacin (Figure 3.9 
C). All three isolates grown in the presence of 2 μg/ml ciprofloxacin failed to grow when 
subcultured on 0%SB agar; in contrast, control isolates grown in the absence of 
ciprofloxacin grew (data not shown).  
 
Figure 3.9: Optimizing experimental conditions for G. vaginalis prophage induction using 
ciprofloxacin. Growth of three G. vaginalis isolates, 3G7 (red) from subgroup A, 3H8 (blue) 
from subgroup B and 3B3 (green) from subgroup C, cultured in 150 μl 0%SB was measured at 
(A) 12 h and (B) 18 h after the introduction of 0.03-2 μg/ml ciprofloxacin during log phase (9 h, 
OD600nm 0.3-0.4). Error bars represent SEM of duplicate cultures. (C) G. vaginalis isolates 
were cultured in 15 ml 0%SB, in the presence (squares) and absence (circles) of 2 μg/ml 
ciprofloxacin introduced at log phase (dotted line, 12 h, OD600nm 0.6, range 0.5-0.7) and 
growth was monitored over 48 h. 
 
The supernatants of the 15 ml cultures of G. vaginalis isolates grown in the presence of 
2 μg/ml ciprofloxacin were investigated for the presence of temperate phages under 
TEM, revealing the presence of phage-like particles from at least one (3G7) out of three 































































































resembled phages belonging to the family of Podoviridae, which shown in Figure 3.10 
C adapted from Lawrence et al. (107), because similar to Podoviridae phages, these 
phage-like particles display a head and a short tail with a length of ~30 nm, which is 
within the typical 10-46 nm range of Podoviridae tails (108). While Podoviridae tails 
often have tail-spikes as can be seen in Figure 3.10 C, tail spikes were not observed in 
any of the micrographs of the phage-like particles obtained in this study. This 
observation was also made in a previous study by Garcia-Heredia et al. (109), where 
phages that were shown to belong to the Podoviridae family by whole genome 
sequence analysis did not display tail-spikes on their micrographs (Figure 3.10 D). With 
the exception of one phage-like particle displayed in Figure 3.10 A, the phage-like 
particles from this study displayed an irregular-shaped head (Figure 3.10 B), and not 
the icosahedral head (Figure 3.10 C) that characterizes Podoviridae phages (108). 
Moreover, the head diameter of these phage-like particles was ~50 nm, which is 10 nm 
below the 60-70 nm range of Podoviridae heads (108). Therefore, these phage-like 
particles could not be confidently classified into any known phage families. Eight G. 
vaginalis isolates could not be infected by these phage-like particles (data not shown). 
To confirm the phage status of these particles, a suitable host to propagate them would 
need to be identified and whole genome sequencing of the phages would need to be 




Figure 3.10: Micrographs G. vaginalis phage-like particles and Podoviridae phages. 
Micrographs of phage-like particles stained with 2% uranyl acetate. These phages-like particles 
were isolated from one G. vaginalis isolate (3G7 from subgroup C) following induction with 2 
μg/ml ciprofloxacin. Two images show (A) 1 and (B) 4 phage-like particles captured from 
different fields of view. (C) General morphology of Podoviridae phages, adapted from Lawrence 










Chapter 4: Discussion 
 
BV is the most common vaginal condition affecting women between the ages of 15-44 
(110). The symptoms of BV are abnormal vaginal discharge with foul odor; although, up 
to 84% of BV-positive women can be asymptomatic (111). Having BV increases a 
woman’s risk of acquiring sexually transmitted diseases, pelvic inflammatory disease 
and adverse pregnancy outcomes (45-49). These grave potential consequences stress 
the need for effective BV treatment. However, this is currently not the case as up to 
~50% of BV-positive women can experience treatment failure within a month or BV 
recurrence within a year (6, 39). Developing effective treatment strategies for BV is 
particularly difficult as its etiology is poorly understood. Although, G. vaginalis is thought 
to play an vital role in the initiation of this polymicrobial condition (44, 63). It is thus 
important to further characterize the role of G. vaginalis in BV, as this could help us 
better understand and treat this condition.  
 
4.1.1 G. vaginalis isolates cluster in four subgroups 
cpn60 phylogenetic analysis of 90 G. vaginalis isolates used in this study revealed the 
presence of four clades. These four clades were previously termed subgroups A, B, C 
and D (27, 72), corresponding to G. vaginalis whole genome sequence clades 4, 2, 1 
and 3 (57), respectively. In this study, subgroup D isolates were the least prevalent, 
while the majority of isolates clustered in subgroup C. Schellenberg et al. (27) found that 
Belgian women had an equal prevalence of subgroup A, B and C isolates (33%, 6/18 for 
each), with an absence of subgroup D isolates. Moreover, they revealed that subgroup 
D isolates were the least prevalent in Canadian (3%, 1/40) as well as Kenyan women 
(13%, 7/54). It is thus not surprising that only 2% (2/90) of G. vaginalis isolates from this 
study clustered in subgroup D, as it seems to be the least prevalent of the four 
subgroups across various geographical locations. This was the first study to 
characterise the prevalence of G. vaginalis within the French population. Previous 
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studies have shown that G. vaginalis subgroup distribution differs by geographical 
location, with subgroups A and C being most prevalent in women from the United States 
and Canada, while subgroup B being most prevalent in Kenyan women (27, 67, 79). As 
the French law forbids any racial parameters within medical files, the diversity of G. 
vaginalis could not be characterized in the context of racial groups. More studies are 
needed to determine G. vaginalis subgroup diversity in more countries, as the 
prevalence of specific G. vaginalis subgroups may explain why BV prevalence is high in 
women of African ancestry but low in women of European ancestry (1). 
 
Based on cpn60 sequences, G. vaginalis from a study by Albert et al. (77) clustered into 
only two subgroups, subgroups A and C. Similarly, G. vaginalis from a study by 
Balashov et al. (67) also clustered into only two subgroups, subgroups C and D. Using 
four G. vaginalis clade-specific primers, Balashov et al. were able to detect subgroup A 
and B isolates in 33% (13/39) of their collection, suggesting that 33% of G. vaginalis 
isolates could not be detected by cpn60 PCR. A similar G. vaginalis cpn60 false-
negative rate (35%, 32/91 isolates) was reported by Janulaitiene et al. (78). While both 
of these studies used different cpn60 primers to the ones used in this study, that 
targeted a different region of the cpn60 gene, 14% (15/109) of G. vaginalis isolates in 
this study were also cpn60-PCR-negative. Since cpn60 is a housekeeping gene, it is 
unlikely that it is absent in some G. vaginalis isolates. What is more likely is that the 
primers used were not able to bind to all cpn60 sequences. It is therefore possible that 
more sensitive cpn60 primers would improve sensitivity. As an alternative, if time had 
permitted, the four clade-specific primers designed by Balashov et al. could have been 
used to genotype the 15 cpn60-PCR-negative G. vaginalis isolates in this this study, as 
these clade-specific primers have successfully been used to genotype G. vaginalis into 
four subgroups, which correspond to the four cpn60-based subgroups, with a false-




4.1.2 G. vaginalis subgroups associated with BV 
The majority of G. vaginalis isolates (69%, 75/109) used in this study were from BV-
positive women, with each isolate being unique to one woman. These isolates were 
purified from vaginal samples collected from women visiting a hospital (Hôpital Arnaud-
De-Villeneuve, CHU de Montpellier, France), that were complaining about their vaginal 
health, thus providing a possible explanation for the bias towards BV-positive women. 
Acknowledging this selection bias, the majority of isolates across all subgroups came 
from BV-positive women, even though subgroups A, B and C also included isolates 
from BV-intermediate and BV-negative women. Additionally, as a result of this bias 
towards isolates from BV-positive women, it was not possible to determine which 
subgroups of G. vaginalis were associated with BV. Based on previous studies, it is still 
unclear which subgroups of G. vaginalis are most predictive of BV. Subgroups B and C 
have been reported as BV-associated two times across three independent studies (67, 
72, 78), while subgroup D has been reported as BV-associated once (67). There is 
general consensus that most women harbor multiple subgroups of G. vaginalis, with 
subgroup diversity being predictive of BV (67, 72, 78, 79). Since only one isolate was 
obtained from each woman in this study, subgroup diversity could not be investigated.  
 
4.2 Sialidase activity detected in G. vaginalis subgroup B and C isolates  
The sialidase gene was detected in 69% (75/109) of isolates in this study, consistent 
with previous reports of sialidase gene detection in 69-75% of G. vaginalis isolates (27, 
81). The sialidase gene was detected in subgroup B and C but not subgroup A or D 
isolates. The lack of sialidase gene detection in subgroup A isolates (97%, 34/35) was 
also reported by Schellenberg et al. (27); however, Schellenberg et al. detected the 
sialidase gene in all (8/8) subgroup D isolates. As only a few subgroup D isolates were 
present in this study and the one by Schellenberg et al., it is possible that future studies 
with a larger subgroup D sample size might reveal that some but not all subgroup D 
isolates harbor the sialidase gene. Furthermore, Schellenberg et al. detected the 
sialidase gene in all 33 subgroup B and 35 subgroup C isolates. However, in this study, 
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the sialidase gene was detected in only 76% (13/17) of subgroup B and 92% (53/58) of 
subgroup C isolates. The same PCR conditions and primers used by Schellenberg et al. 
were used in this study, thus making it unlikely that experimental differences caused 
these discrepancies. Nonetheless, different sialidase primers could be used to test for 
the presence of the sialidase gene in the sialidase-PCR-negative isolates in this study. 
A total of 10/34 isolates that failed the sialidase PCR also failed the cpn60 PCR, 
suggesting that another reason for the lack of sialidase gene detection could be due to 
PCR failure as a result of the bad quality of the extracted DNA. Checking the quality of 
the DNA extracted from the G. vaginalis isolates may have given some insight into why 
some of the isolate’s sialidase PCR was negative. 
 
Sialidase activity was detected in 25% (27/109) of G. vaginalis isolates, which is 
consistent with a previous report by Schellenberg et al. (27) of sialidase activity 
detection in 35% (36/112) of G. vaginalis isolates. Sialidase activity was detected in 
36% (27/75) of sialidase-PCR-positive isolates, again consistent with the previously 
reported sialidase activity detection in 47% (36/77) of sialidase-PCR-positive isolates 
(27). While Schellenberg et al. found that sialidase activity was disproportionately 
detected in subgroup B (100%, 33/33) and C (9%, 3/35) isolates, sialidase activity was 
detected at similar frequencies in subgroup B (41%, 7/17) and subgroup C (31%, 18/58) 
isolates in this study. Schellenberg et al. remarked that all subgroup C isolates with 
detectable sialidase activity were sampled from Belgian women but not from any of the 
Kenyan or Canadian women included in their study. This suggests that sialidase activity 
of G. vaginalis subgroups may be cohort-dependent. In this study, subgroup C sialidase 
sequences cluster together, separately from subgroup B sequences. The detection of 
similar sialidase activity levels between subgroup B and C isolates in this study 
suggests that the phylogenetic distinctness of subgroup B and C sialidase sequences 
merely reflect evolutionary divergence between the two subgroups, rather than 
functional differences in sialidase activity. Consistent with the lack of sialidase gene 
detection by PCR in all subgroup A and D isolates, sialidase activity was also not 
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detected in these subgroups. This suggests that G. vaginalis subgroups A and D may 
not be actively involved in BV, as sialidase activity is considered a marker of BV (26).  
 
The reason behind the detection of sialidase activity in only 36% of the sialidase-PCR-
positive G. vaginalis isolates in this study is yet to be established. This lack of sialidase 
activity does not seem to be related to BV status, as sialidase activity was detected at 
similar frequencies in isolates from women of all BV states. However, it is important to 
note that this may differ in vivo. Others have hypothesized that sialidase expression 
may require stimulation by unknown factors that can be turned on or off based on in 
vivo environmental conditions; although, this hypothesis is yet to be investigated (81). 
Comparing the sialidase gene promoter regions of G. vaginalis isolates could help 
identify such factors. As G. vaginalis subgroups B and C isolates are phylogenetically 
closely related, the detection of sialidase activity in isolates from these subgroups (but 
not subgroups A and D) suggests that sialidase activity may be a shared ancestral 
virulence trait, specific for G. vaginalis subgroups B and C. 
 
4.3 Biofilm formation by G. vaginalis isolates from all subgroups  
This study is the first to quantify and compare biofilm formation of G. vaginalis 
subgroups, revealing that all subgroups appear to be similar in their ability to form 
biofilm. These data support a previous qualitative study that detected the presence of 
biofilm in isolates from all G. vaginalis subgroups (72). The ability of G. vaginalis 
subgroup B and C isolates to form biofilm, as well as the detection of sialidase activity in 
these subgroups suggests G. vaginalis subgroups B and C as the most likely to be 
involved in BV (26, 84) 
 
G. vaginalis isolates from both BV-negative (Nugent 0-3) and BV-positive women 
(Nugent 7-10) were able to form biofilm at similar quantities. This observation was also 
made in a previous study by Castro et al. (112), who further reported that G. vaginalis 
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isolates from BV-positive women were five times more adherent to epithelial cells than 
G. vaginalis isolates from BV-negative women. While G. vaginalis isolates from both 
groups of women appear to be able to form biofilms, the findings by Castro et al. 
suggest that biofilms formed by BV-negative women may be easier to excrete as they 
are less adherent to the vaginal epithelial wall compared to biofilms formed by BV 
positive women, which are able to adhere to the vaginal epithelium and form stable 
biofilms that support the growth of other pathogenic BV-associated bacteria.  
 
Bacteria are known to form biofilms on the surfaces of polypropylene microcentrifuge 
tubes (113). In this study, G. vaginalis isolates were cultured in microcentrifuge tubes 
and then subcultured in 96 well microtiter plates before biofilm formation was quantified 
(102). By visual inspection, it was clear that virtually all G. vaginalis isolates could form 
biofilm on the surfaces of microcentrifuge tubes. However, despite multiple optimization 
attempts, the protocol used underestimated biofilm formation, especially by weak biofilm 
producers, as biofilm could easily detach from the wells during the protocol’s two 
washing steps. This protocol was chosen as it has been used multiple times to quantify 
G. vaginalis biofilms (66, 72, 88, 112, 114). A fixation step should be investigated in 
future experiments, as this could minimize biofilm loss. Another method that is 
commonly used to detect G. vaginalis biofilms is fluorescence in situ hybridization 
(FISH), whereby biofilms are detected by confocal microscopy, using florescent probes 
that bind rDNA or rRNA sequences that are species-specific. This method was not used 
in this study as it is typically used to detect the presence or absence rather than the 
quantity of biofilm (7, 81, 85, 87, 115).  
 
A limitation of this study was that biofilm was measured in only one growth medium 
(5%-blood-supplemented Schaedler medium) and it is known that biofilm formation is 
growth medium-dependent. Previous studies have noted that G. vaginalis formed 
substantially more biofilm in brain heart infusion broth supplemented with 0.25% (w/v) 
maltose or 1% (w/v) glucose compared to other tested growth mediums, including Todd 
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Hewitt broth and ATCC broth #1685 (72, 112, 116). In this study, G. vaginalis biofilm 
was measured in 5% blood-supplemented Schaedler broth, as G. vaginalis isolates 
grew faster and to a higher optical density in this growth medium compared to in brain 
heart infusion medium supplemented with 0.1% (w/v) starch and 0.5% (w/v) yeast (data 
not shown). Nonetheless, in future studies, biofilm should be quantified using different 
growth mediums, preferably ones most representative of in vivo conditions.  
 
Another limitation of this study was that biofilm was only measured at pH 7.4, the pH of 
5%-blood-supplemented Schaedler medium. Gottschick et al. (114) recently noted that 
G. vaginalis’ biofilm forming ability increases with increasing pH, being lowest at pH 4.5 
and highest at pH 7, the upper and lower limits of their tested pH range. This 
observation is particularly relevant in the context of BV, as BV is characterized by an 
increase in vaginal pH from 4-5 towards a pH of 6-7 (10, 117). It is important to further 
investigate the effect of pH on G. vaginalis’ biofilm forming ability and compare if there 
are any differences seen in isolates from different subgroups. If it is found that there are 
subgroups that are able to form biofilm at low pH levels, this would suggest these 
subgroups to be the pioneers of biofilm formation that subsequently promote the growth 
of other BV-associated bacteria, outcompeting commensal lactic-acid-producing 
species that maintain the acidic vaginal environment, thus serving as a potential 
explanation for the shift from low to high pH. 
 
4.4 Antibiotic susceptibility of G. vaginalis isolates  
Antibiotic susceptibility of G. vaginalis isolates to metronidazole and clindamycin was 
tested, as these are the first-line recommended antibiotics for the treatment of BV (110). 
In addition, antibiotic susceptibility of G. vaginalis isolates to moxifloxacin and 
augmentin were also tested, as these antibiotics are being explored as alternative 
treatments for BV (90, 91), in light of the emergence of metronidazole and clindamycin 
resistance (40, 62). Of the 109 G. vaginalis isolates used in this study, 64 could not form 
a lawn on 5% blood-supplemented Brucella agar, thus antibiotic susceptibility was 
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measured for only 45 G. vaginalis isolates. It is unknown why more than half of the 
isolates in this study could form lawns. Various variables including the type of agar 
medium, dilution medium (saline versus Schaedler and Müller Hinton), temperature of 
agar at the time of plating the lawn, and anaerobic sachet lot were investigated as 
potential reasons but none of these variables appeared to be the cause. Increasing or 
decreasing the inoculum (that is, McFarlane unit of 0.5 or 2) did not change the results. 
Even though it was unlikely that the isolates had become less viable over time, new 
isolate cultures were produced but even they were unable to form lawns. These 
experiments were conducted with a time limit of two months as they were carried out 
during an internship in France. It is possible that further experiments testing other 
variables could have elucidated why some isolates were not able to form lawns. 
 
G. vaginalis isolates were the most frequently resistant to metronidazole (71%, 32/45) 
compared to all the other antibiotics, which reflects the fact that metronidazole is the 
most commonly used antibiotic to treat BV (110). Using 32 μg/ml as a breakpoint for 
resistance as in this study, a previous study also noted a similarly high amount of 
metronidazole resistance (61%, 53/87) amongst G. vaginalis isolates (41). Moreover, 
60% (27/45) of isolates were highly resistant to metronidazole (MIC ≥ 256 μg/ml), a 
common phenomenon that has been observed in ~55% of isolates in other studies (41, 
42). Metronidazole resistance was present across all subgroups of G. vaginalis tested in 
this study. However, small sample size limited the statistical power to compare 
metronidazole resistance across the four subgroups of G. vaginalis. Schuyler et al. (41) 
recently found all 22 subgroup A and 15 subgroup D isolates to be resistant to 
metronidazole, compared to only 7% (1/14) of subgroup B and 43% (16/37) of subgroup 
C isolates. As G. vaginalis biofilms are often recovered from the genital tracts of BV-
negative women after metronidazole treatment (87), it is likely that the G. vaginalis 
biofilms that persist in these women belong to the intrinsically resistant subgroups A and 
D. Persistence of these metronidazole-resistant biofilms would most likely support the 
growth of other BV-associated bacteria, leading to the re-emergence of the 
polymicrobial biofilm associated with BV and subsequently, BV recurrence. 
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Metronidazole is part of the nitromidazole group of antibiotics, whose mechanism of 
action requires the reduction of their nitro group (typically by anaerobes as they have a 
higher reducing potential than aerobes) before oxidizing bacterial DNA, causing DNA 
strand breaks (118). Several mechanisms of resistance by anaerobes to nitromidazoles 
have been proposed, including: (i) decreased activation or increased inactivation of the 
drug; (ii) decreased uptake and increased efflux of the drug and (iii) increased DNA 
damage repair by bacteria (119). Seven genes conferring resistance to nitromidazoles, 
termed nimA – nimG, have been identified, which encode a reductase that inactivates 
nitromidazole into a non-toxic derivative. A previous study found that, while these genes 
were absent from all 145 vaginal samples from BV-negative women, the were found in 
only 1.4% (2/144) of samples from BV-positive women (40). It is thus unlikely that nim 
genes are the reason for the high level of G. vaginalis metronidazole resistance 
observed in this study. A recent study suggested that G. vaginalis may use its cas 
genes to mitigate the DNA-damaging effects of metronidazole, as 7 cas genes (cas1 to 
cas3 and casA to casD) were found to be up-regulated in the genital tracts of women 
who experienced BV treatment failure compared to those who were cured (62). Cas 
genes are nucleases, best known for their role in genome editing as part of the 
CRISPR-cas system (93). However, cas1 proteins can also play a role during DNA 
excision repair (120). The functional role of the up-regulated G. vaginalis cas proteins 
following metronidazole treatment remains to be investigated (62). 
 
None of the G. vaginalis isolates that were tested in this study were resistant to 
clindamycin. Using 4 μg/ml as a breakpoint for resistance (as in this study), 1.5-6%  of 
G. vaginalis isolates were found to be resistant to clindamycin in previous studies (42, 
43). Clindamycin is part of the lincosamides group of antibiotics, which bind to the large 
ribosomal subunit, inhibiting protein synthesis (121). Bacterial clindamycin resistance 
genes are called erm genes, which encode rRNA methylases that change the structure 
of the antibiotic binding site (40). Erm genes were found to be present in 62% (90/144) 
of vaginal samples from BV-positive women, while being present in only 14% (20/145) 
of samples from BV-negative women (40). Moreover, G. vaginalis are known to harbor 
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erm genes (122). These reports are inconsistent with the absent to low level of 
clindamycin resistance of G. vaginalis isolates observed in this study as well as others 
(42, 43). It is possible that the transcription of erm genes is not constitutive. 
Alternatively, G. vaginalis isolates in this collection may lack erm genes. Both 
hypotheses could be tested by running qPCR on this collection of G. vaginalis isolates, 
using erm-gene-specific primers. Nonetheless, the absent to low level of clindamycin 
resistance compared to metronidazole resistance amongst G. vaginalis isolates 
suggests that clindamycin remains an acceptable (and perhaps even a better) 
alternative to metronidazole in the treatment of BV. 
 
Only 9% (4/45) of G. vaginalis isolates were resistant to moxifloxacin using 0.5 μg/ml as 
the breakpoint for resistance. While this breakpoint for resistance is not as conservative 
as the breakpoints for resistance for the other tested antibiotics, it is the only 
moxifloxacin breakpoint for G. vaginalis resistance that could be found in previous 
literature (103). Moxifloxacin is part of the fluoroquinolone group of antibiotics, which 
inhibit DNA gyrase and topoisomerase IV activity, enzymes that stabilize the bacterial 
DNA helix as it unwinds during DNA replication (123). The most studied mechanisms of 
bacterial resistance to moxifloxacin are gyrA and parC mutations, which alter the 
moxifloxacin binding sites of DNA gyrase and topoisomerase IV proteins (124). 
Sequencing the gyrA and parC genes of G. vaginalis could shed light on whether gyrA 
and parC mutations are the mechanisms G. vaginalis uses to resist moxifloxacin 
activity. This is not the first study to investigate moxifloxacin in the context of BV. 
Swidinski et al. (90) reported that 75% (15/20) of BV-positive women were successfully 
treated for BV with 400mg moxifloxacin taken orally for 5 days. This, in addition to the 
observation made in this study that moxifloxacin was superior to metronidazole with 
regards to G. vaginalis susceptibility, prompts the suggestion that moxifloxacin should 




All G. vaginalis isolates tested in this study were sensitive to augmentin. This is 
consistent with a previous report where, using the same 8 μg/ml breakpoint for 
resistance as in this study, all 67 tested G. vaginalis isolates were sensitive to 
augmentin (42). Augmentin is a combination of amoxicillin and clavulanic acid. 
Amoxicillin is part of the penicillin group of antibiotics, which inhibit cell wall synthesis 
(125). Some bacteria can resist the activity of penicillins using β-lactamases, enzymes 
that degrade the β-lactam ring of penicillins (125). Clavulanic acid inactivates β-
lactamases thereby preventing them from degrading amoxicillin. However, bacteria can 
also develop resistance to clavulanic acid by overexpressing β-lactamases or modifying 
the β-lactamase active site of clavulanic acid (126). Nonetheless, augmentin appears to 
be superior to amoxicillin in the treatment of BV, as in a previous study, 37% (3/8) of 
BV-positive women treated with amoxicillin experienced treatment failure, while all 6 
women treated with augmentin were cured (91). Taken together, augmentin should be 
further studied in the context of BV, as it is an excellent candidate as an alternative to 
metronidazole in the treatment of BV.  
 
4.5 Prophage induction of G. vaginalis  
There have been reports of an abundance of prophage sequences in the genomes of G. 
vaginalis (59, 96); however, phages of G. vaginalis have never been isolated. One of 
the ways Lactobacillus species (particularly, L. gasseri) are thought to suppress the 
growth of G. vaginalis is by producing hydrogen peroxide (98). Hydrogen peroxide is a 
reactive oxygen species that generates hydroxyl radicals, molecules that oxidize and 
damage DNA by causing DNA strand breaks, intra- and inter-strand crosslinking and 
base modifications (127). Upon encountering DNA damage, bacteria activate their SOS 
response, a network of least 40 genes that repair damaged DNA (128). The SOS 
response can trigger the inactivation of prophage repressor genes, resulting in 
prophage induction (99). Hydrogen peroxide is known to induce prophages (97). It was 
thus hypothesized that hydrogen peroxide released into the supernatants of L. gasseri 




Not all DNA-damaging agents lead to prophage induction and different prophage-
inducing agents can induce different prophages from a single bacterial isolate (101, 
129). This is probably because prophage-inducing agents damage DNA using a variety 
of mechanisms. UV radiation, mitomycin C and ciprofloxacin are other DNA-damaging 
agents known to induce prophages (99). UV radiation crosslinks adjacent pyrimidine 
DNA bases, preventing them from binding to their complementary bases (130). 
Mitomycin C is an antitumor antibiotic that alkylates and crosslinks DNA strands (131). 
As with moxifloxacin, ciprofloxacin is part of the fluoroquinolone group of antibiotics that 
destabilize the DNA helix as it unwinds during DNA replication, resulting in double-
stranded DNA breaks (132). The ability of L. gasseri supernatant, UV radiation, 
mitomycin C and ciprofloxacin to induce prophages of G. vaginalis isolates was tested. 
UV radiation, mitomycin C and ciprofloxacin were chosen as they were found to be the 
most commonly used prophage-inducing agents in literature; however, other known 
prophage-inducing agents that can be tested for their ability to induce prophages of G. 
vaginalis in future studies are quinolone antibiotics such as norfloxacin, levofloxacin, 
moxifloxacin, nalidixic acid and oxolinic acid as well as agents that generate reactive 
oxygen species such as paraquat (129, 133).    
 
Prophage-inducing agents that cause DNA damage are usually added to early log-
phase bacterial cultures that are undergoing DNA replication, in order to maximize DNA 
damage, and thus, maximize the rate of prophage induction (101). In this study, early 
log-phase growth of G. vaginalis cultures in Schaedler medium was determined to be 
around 9 h. For other bacterial species, productive prophage induction is usually 
suggested by a transient increase followed by a decrease in bacterial cell density, which 
occurs soon after the addition of a prophage-inducing agent (101). Since prophages 
against G. vaginalis have never been induced, it is unknown when this increase and 
decrease in cell density occurs. Therefore G. vaginalis isolates were monitored for 
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evidence of prophage induction until they were well into their stationary phase, that is, 
after at least 24 h. 
 
Log-phase cultures of G. vaginalis isolates did not grow in the presence of 50% L. 
gasseri supernatant, while isolates cultured in the presence of lower concentrations of 
L. gasseri supernatant (0.03-33%) grew similarly to isolates cultured without L. gasseri 
supernatant. G. vaginalis isolates cultured in the presence of 50% L. gasseri 
supernatant were analyzed under TEM but no temperate phages were observed. To 
successfully induce prophages, DNA-damaging agents need to be used at 
concentrations that are high enough to induce prophages but are sub-lethal to the 
bacterial hosts, as to allow bacteria to mitigate DNA damage long enough for successful 
prophage induction to occur (101). The specific L. gasseri isolate used in this study 
produces ~10µM hydrogen peroxide, which is lower than hydrogen peroxide 
concentrations (50-1000µM) that have successfully been used to induce prophages of 
other bacterial species (97, 134, 135). If time had permitted, different concentrations of 
hydrogen peroxide alone could have been tested for their ability to induce prophages of 
G. vaginalis, as it is possible that hydrogen peroxide in the 50% L. gasseri supernatant 
was too low to cause DNA damage and prophage induction of G. vaginalis isolates. 
Other virulence factors, such as lactic acid and bacteriocins produced by L. gasseri 
(136), could be responsible for the observed inhibition of G. vaginalis growth by the L. 
gasseri supernatant.  
 
G. vaginalis isolates exposed to up to 60 sec of UV radiation grew similarly to isolates 
that were not exposed to UV radiation, suggesting that UV radiation neither caused 
prophage induction nor inhibited cell division. It is unlikely that this was due to 
suboptimal duration of isolates under UV radiation as isolates were irradiated for 5-60 
sec and optimal duration for prophage induction using UV radiation is usually around 5-
15 sec for other bacteria (101). While UV-C radiation at 254 nm has previously been 
used to induce prophages of other bacteria (137), it is possible that G. vaginalis is 
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insensitive to UV radiation at 254 nm and that a stronger wavelength is needed to cause 
DNA damage and prophage induction. Prophage induction by UV radiation has been 
extensively studied in Escherichia coli and it is apparent that having mutations in 
bacterial genes involved in the SOS response to UV radiation (termed umuA-C genes) 
can make cells insensitive to UV DNA damage, leading to unsuccessful prophage 
induction attempts (138). G. vaginalis isolates could be screened for the presence of 
such mutations in the future, as this could explain why G. vaginalis growth was 
unaffected by UV radiation. 
 
G. vaginalis isolates cultured in the presence of 0.5 μg/ml mitomycin C grew similarly to 
isolates cultured without mitomycin C, suggesting that G. vaginalis isolates were 
insensitive to mitomycin C at this concentration. Higher concentrations of mitomycin C 
(1-16 μg/ml) decreased G. vaginalis growth in a dose-dependent manner, suggesting 
that G. vaginalis isolates were sensitive to the DNA-damaging effects of mitomycin C. 
However, since isolates cultured in the presence of all tested mitomycin C 
concentrations continued to grow for 18 h after the addition of mitomycin C, it was 
unlikely that prophage induction had occurred since a decrease, and not an increase, in 
cell density shortly after the addition of a prophage-inducing agent signals productive 
prophage induction (101). The absence of temperate phages in G. vaginalis isolates 
cultured in the presence of 0.5 μg/ml or 8 μg/ml mitomycin C was confirmed by TEM 
analysis. It was previously reported that 97% (38/39) of the published G. vaginalis 
genomes harbor up to 33 prophage sequences (59), suggesting a high probability of the 
presence of prophages in the three G. vaginalis isolates tested in this study; although, 
whole genome sequencing of these isolates is necessary to confirm this. Mitomycin C at 
the tested wide concentration range of 0.05-16 μg/ml was unable to induce prophages 
of up to 15 other G. vaginalis isolates (data not shown). This concentration range is well 
within the normal range of 0.5-3 μg/ml in which mitomycin C is a potent prophage 
inducer for other bacteria, including Bifidobacterium species (101, 105), the closest 
phylogenetic relatives of G. vaginalis (106). The reason behind the ability of mitomycin 
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C to inhibit growth but not induce prophages of G. vaginalis isolates is yet to be 
determined.  
 
G. vaginalis isolates cultured in the presence of 2 μg/ml ciprofloxacin grew slower and 
to a lower stationary-phase cell density than isolates cultured without ciprofloxacin. 
Instead of the expected decrease in cell density following the addition of ciprofloxacin in 
the event of prophage induction (101), G. vaginalis isolates in this study maintained 
stationary phase until at least 36 h. Although, there have been reports of successful 
prophage induction in cells maintaining stationary phase or incomplete cell lysis of 
bacterial cultures following the addition of a prophage-inducing agent (104, 139). In this 
study, TEM analysis of at least one out of three G. vaginalis isolates (3G7) cultured in 
the presence of 2 μg/ml ciprofloxacin revealed the presence of phage-like particles. 
These particles are referred to as phage-like as they could not be confidently classified 
into any known phage families. Although, these phage-like particles present in head-tail 
structure, a defining characteristic of Myoviridae, Siphoviridae and Podoviridae phage 
families under the order of Caudovirales (140). These phage-like particles most 
resemble phages belonging to the family of Podoviridae, as they have a ~30 nm long 
tail that is shorter than the 80-455 nm Myoviridae and 65–570 nm Siphoviridae tail 
ranges, but is within the 10-46 nm Podoviridae tail range (108). However, their tails lack 
tail-spikes, which are a defining characteristic Podoviridae phage tails (107). Although, 
tail-spikes are not always clearly defined under TEM (109). The phage-like particles 
from this study generally displayed a ~50 nm wide, irregular-shaped head, and not the 
60-70 nm wide, icosahedral-shaped head that characterizes Podoviridae phages (108), 
thus preventing these phage-like particles from being classified as Podoviridae phages. 
Eight cultures of G. vaginalis isolates were screened for their use as hosts to propagate 
the phage-like particles; however, none could be infected by the phage-like particles 
(data not shown). The G. vaginalis isolate from which the phage-like particles were 
obtained (3G7) cannot be used as a host to propagate them, as prophages cause 
superinfection exclusion, a process whereby prophages produce proteins that prevent 
infection of the same or similar phages into the same host cell (141). This experiment is 
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yet to be repeated using a wider panel of G. vaginalis isolates (or closely related 
species) that could be screened for their use as a host to propagate these phage-like 
particles in order to yield enough phage DNA to conduct whole genome sequencing, 
which is necessary to confirm the phage status of these phage-like particles. 
 
4.6 Prospectives 
In order to improve the current poor treatment outcomes of BV, research efforts should 
be directed towards strategies that aim to restore and maintain healthy vaginal 
microbiota as well as strategies that aim to prevent and eradicate the polymicrobial 
biofilm that characterizes BV. Alternative treatment strategies such as the use of 
probiotics, phage therapy and anti-biofilm agents have the potential to reduce BV 
recurrence, if used in combination with antibiotic therapy (142). Probiotics are live 
micro-organisms that are beneficial to the host when consumed at the right amounts 
(143). Studies evaluating long-term administration of probiotic lactobacilli, included in 
feminine hygiene products or food consumed regularly, such as yogurt, milk and ice 
cream, have shown controversial but overall promising results with regards to probiotics 
preventing, treating and reducing the recurrence of BV (143-145). 
Phage therapy, which is the use of phages to treat bacterial conditions (146), has been 
suggested as an alternative BV treatment strategy (147). Unlike antibiotics, which tend 
to be broad-spectrum, phages tend to have a narrow host range, being species- or even 
strain-specific (148). Thus, phage cocktails targeting BV-associated bacteria but not 
commensal lactic acid-producing species could potentially restore dysbiotic vaginal 
microbiota to its healthy state. Another feature that makes phages ideal agents in 
preventing BV recurrence is their ability to eradicate biofilms. While this is usually 
credited to their ability to self-amplify at the target site to numbers high enough to 
destroy the entire biofilm (89), phages can encode depolymerases that degrade 
extracellular polymeric substances in the biofilm matrix, allowing phages to move 
around in the biofilm, in addition to degrading bacterial cell surface polymers, allowing 
phages to attach to their bacterial targets (149). The isolation of virulent phages against 
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vaginal bacteria has been an elusive task. However, depolymerases isolated from 
phages from other human compartments could be effective at disrupting BV biofilms 
and should thus be investigated.  
 
Other anti-biofilm agents such as antibacterial hydrolases and antiseptics have been 
investigated for their ability to prevent and eradicate BV biofilms; however, the 
amphoteric tenside, cocoamphoacetate, was the only compound that showed great 
promise in vitro, where it completely prevented G. vaginalis biofilm formation and 
dissolved over of 50% of biofilm established over 20 h (114). However, in a follow up 
clinical trial, cocoamphoacetate-containing pessaries reduced biofilm formation but were 
unable to prevent BV recurrence when administered intra-vaginally to BV-positive 
women treated with metronidazole (150). The pessaries were only taken for three 
weeks after metronidazole treatment; it is possible that prolonging the treatment could 
have improved treatment outcomes. A different strategy to prevent BV biofilms could be 
to inhibit sialidase activity, as sialidase is thought to degrade vaginal mucus, allowing G. 
vaginalis to attach to the vaginal epithelial layer and form biofilms (81). The sialidase 
inhibitor, Zanamavir, decreased G. vaginalis sialidase activity by 30% in vitro (151). 
However, the functional association of sialidase activity and biofilm formation in the 
context of BV is yet to be confirmed in vivo. 
 
4.7 Conclusion   
Based on cpn60 phylogenetic analysis, 90 G. vaginalis isolates used in this study 
clustered into four clades, referred to as subgroups A-D. Isolates from all subgroups 
produced similar amounts of biofilm; however, sialidase gene and activity was detected 
in subgroup B and C isolates only. As the presence of biofilm and sialidase activity are 
two hallmark traits of BV (26, 84), these data suggest G. vaginalis subgroups B and C 
as most likely to be involved in BV. G. vaginalis from subgroups B and C probably 
secrete sialidase during BV, an enzyme that is thought to degrade the protective mucus 
layer lining the vaginal tract, allowing G. vaginalis (from all four subgroups) and other 
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BV-associated bacteria to attach to the vaginal epithelial layer and form a polymicrobial 
biofilm. Metronidazole resistance was observed in the majority of G. vaginalis isolates 
(71%, 32/45) across all subgroups, providing a possible mechanism for how G. 
vaginalis biofilms can persist in the vaginal tracts of women treated for BV with 
metronidazole (87). In contrast, all G. vaginalis isolates were sensitive to clindamycin, 
which remains an acceptable alternative to metronidazole in the treatment of BV. 
Moxifloxacin and augmentin are also suggested as potential alternatives to 
metronidazole in the treatment of BV, as both antibiotics displayed microbiological 
efficacy against G. vaginalis isolates in this study, and have previously demonstrated 
clinical efficacy in the treatment of BV (90, 91). However, as with metronidazole, all 
these antibiotics are bound to suffer the same fate of being rendered ineffective by the 
emergence of antibiotic resistance. Moreover, antibiotics are not able to entirely destroy 
the polymicrobial biofilm that forms during BV, which contributes to the high BV 
recurrence rate (39, 87, 90). There is thus a great need to look into sustainable 
alternative treatment strategies in hopes of improving the current poor treatment 
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